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Cancer fights back: Drug resistance and metastasis
Cancer is an ancient disease that has been thought to be incurable for 
centuries. Even today, despite all the technological advancements and medical 
discoveries, cancer is the leading cause of death worldwide.
 The oldest and most straightforward treatment method for cancer is 
surgery. Different surgical methods can be used to remove the whole or parts 
of tumors for curative or palliative purposes. Owing to the modern imaging 
techniques such as magnetic resonance imaging (MRI), computed tomography 
(CT), and positron emission tomography (PET), it is now possible to visualize the 
margins of tumors to maximize accuracy and precision in surgeries. However, 
even centuries ago it was clear to healthcare specialists that surgical removal 
of tumors is not always the end of cancer. Cells scattered from the primary 
tumor often cause relapse of the disease at the same or a distant site. In the 
last century, several other strategies have been developed to treat cancer, and 
newer, more effective approaches are rapidly being innovated. 
 Cytotoxic chemotherapy (referred to as chemotherapy from here on) 
and radiotherapy were the first nonsurgical anti-cancer treatments developed. 
These typically target fast-replicating cells and are therefore mainly destructive 
to cancer cells that have unlimited replication potential. Chemotherapy and 
radiotherapy are now mostly being used in an adjuvant setting to prevent 
recurrence after surgical removal of tumors or in a neoadjuvant setting to shrink 
large tumors prior to surgery. In the last few decades, alternative treatment 
options have arisen such as endocrine treatment, monoclonal antibodies, 
vaccines and small molecule inhibitors. These methods are being used in 
combinations based on the origin, type, stage and molecular background of 
tumors in an effort to obtain optimal results. Such targeted therapies greatly 
improved response rates and caused milder side effects than chemotherapy 
or radiotherapy. However, regardless of the treatment strategy, there are two 
common challenges clinicians face: drug resistance and metastasis.
Drug resistance in cancer
Drug resistance is a phenomenon where a disease does not respond to an 
administered drug at any point during the course of a treatment. In the context 
of cancer, drug resistance is the focus of extensive research since many tumors 
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are, or become, insensitive to available therapies. Resistance can be caused by 
mechanical reasons that make the tumors inaccessible to drugs as is the case 
in pancreatic cancer [1]. However, drug resistance in cancer is generally due to 
intrinsic or acquired molecular mechanisms.
 Cancer is usually a heterogeneous disease formed by groups of cells 
with various molecular profiles and therefore with different capabilities [2]. 
For instance, as will be discussed later in this chapter, some cells in a tumor 
are more motile, resulting in an invasive phenotype and possibly metastasis. 
Others have stem cell-like characteristics, which allow them to regenerate 
and differentiate into different types of tumor cells. Intrinsic resistance, also 
called primary or innate resistance, is associated with all or a subpopulation 
of the cancer cells being unresponsive to a drug. Such tumors may show no 
response at all or shrink in the initial phase of treatment but then regrow with 
no sensitivity to the same, or similar, treatments. Resistant cells survive due to 
a distinguishing intrinsic feature such as an extra mutation, or the activation 
of a parallel pathway or a feedback mechanism that compensates for the loss 
of the initial way of survival. Acquired, or adaptive resistance occurs when, 
under the pressure of a drug treatment, some cancer cells find a way to survive 
the treatment, resulting in a clonal outgrowth of this population. Similar to 
intrinsic resistance mechanisms, acquired resistance can be due to secondary 
mutations or compensatory pathway activation. 
Chemotherapy and radiotherapy resistance
Chemotherapy and radiotherapy are the oldest nonsurgical methods of 
anti-cancer treatment. Radiotherapy functions by inducing an irreparable 
amount of single and double strand breaks in the DNA, resulting in cell death. 
Chemotherapy blocks cellular reproduction by influencing the genomic 
integrity in several different ways. For instance, alkylating agents such as 
cisplatin crosslink the strands of DNA in a cell cycle-phase-independent 
manner and, upon proliferation, inhibits DNA, RNA and protein synthesis, 
whereas antimetabolites like methotrexate interfere with DNA synthesis and 
are therefore only effective on the cells that are in the S-phase of the cell cycle 
[3]. Chemotherapy has been demonstrated to be very effective against some 
malignancies, whereas their effectiveness on other tumors is less pronounced. 
On one hand, the average contribution of chemotherapy to 5-year survival of 
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adult cancer patients is calculated to be as low as 2.1% in the US and 2.3% in 
Australia [4]. On the other hand, chemotherapy remains the backbone of cancer 
treatment despite the low success rates and devastating side effects. This is 
partly due to lack of better options, but also because it is still unclear which 
tumors respond to chemotherapy and to what extent. For example, in the 
adjuvant setting, chemotherapy improves survival of breast cancer patients 
[5], but fails to provide a significant survival benefit to rectal cancer patients 
[6]. As opposed to most solid tumors, chemotherapy is the primary course of 
curative treatment against non-solid tumors such as leukemia and lymphoma. 
For instance, if diagnosed sufficiently early, the five-year survival rate is as 
high as 90% for patients with and acute lymphoblastic leukemia (ALL), the 
most common childhood malignancy [7, 8]. Despite these success rates, 
therapy resistance is still a concern and hence, patients with drug refractory 
disease have poor prognosis.  
 Resistance mechanisms to chemotherapy and radiotherapy mainly 
include deregulation of cell death programs [9, 10], mutations in DNA damage 
response (DDR) pathways [11], hypoxia [12], overexpression of drug transporters 
[13], and drug inactivation [14] as well as epithelial-mesenchymal transition 
(EMT) [15], which will be discussed in more detail later.
 In order to evade programmed cell death caused by chemo or 
radiotherapy, cancer cells can manipulate components of these pathways. 
Inactivating pro-apoptotic proteins or activating anti-apoptotic proteins is 
a common mechanism of both acquired and intrinsic therapy resistance. 
Overexpression of prosurvival Bcl-2 family members is often observed in 
cancer cells that do not undergo apoptosis upon drug exposure [16, 17]. Lower 
Bcl-2 expression levels are also found to be correlated with a stronger therapy 
response [18-20].
 Secondly, DDR is a complex network of sensor and repair proteins that 
are responsible of cell fate decisions upon DNA damage. Breaks in the DNA 
that are induced by chemo or radiotherapy are either repaired by this network, 
or in cases of intense damage, apoptosis is induced. A highly efficient DDR 
results in the survival of the cells with severely damaged DNA and therefore is 
correlated with therapy resistance and poor prognosis [21, 22].
 Hypoxia is yet another factor that protects tumors from cytotoxic 
drugs. Well-oxygenated tumors typically respond well to chemotherapy and 
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radiotherapy [23, 24], whereas hypoxic tumor cells are protected from the 
cytotoxic effects of these therapies. One explanation for this protection is the 
fact that the activity of radiotherapy and some chemotherapy drugs depend 
on generation of free radicals in the presence of oxygen. Another reason why 
hypoxic cells are less affected by therapy is elevated hypoxia inducible factor 
1 (HIF1) expression. Decreased oxygen availability induces HIF1 expression, 
which indirectly activates tumor-promoting events such as proliferation, 
migration, invasion and angiogenesis. Hypoxia has been linked to therapy 
resistance and poor prognosis in several cancer types, such as head and neck 
cancer [25], lung cancer [26, 27], cervical cancer [28] and soft tissue sarcoma 
[29]. 
 Another major challenge in chemotherapy is overexpression of drug 
transporters, resulting in multidrug resistance (MDR). Drug transporters like 
ATP-binding cassette (ABC) transporters are transmembrane proteins that 
regulate the efflux of the cell. Pumping of the chemotherapeutic agents by 
these transporters out of the cells before they are exposed to the negative 
effects of the drugs is a prominent chemotherapy resistance mechanism 
[30]. The most thoroughly studied ABC transporters in the context of MDR are 
P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and multidrug 
resistance protein 1 (MRP1). Studies in cell lines [31-33] and mouse models 
[34-36] show that aberrations in these transporters cause chemotherapy 
resistance and that resensitization can be achieved once the transporters are 
depleted by genetic intervention [36, 37] or inhibited by small molecules [38, 
39]. Moreover, several studies and meta-analyses provide ample evidence that 
expression levels of ABC transporters are correlated with therapy resistance 
[40-47]. However, while an inhibitor against BCRP or MRP1 has not yet been 
tested in the clinic, trials designed to assess the effect of P-gp inhibition have 
so far been disappointing owing to a number of reasons such as (lack of) drug 
potency, toxicity, and trial design [48].
 Finally, some cancers are unresponsive to treatment due to drug 
inactivation. Some chemotherapy drugs like tamoxifen require metabolic 
activation to become effective [49, 50]. Drug inactivation in cancer cells 
occurs via manipulation of pathways that mediate drug activation. Increased 
detoxification [51, 52] and glucuronidation [53, 54] are some examples of drug 
13 
Ch
ap
te
r 1
inactivation mechanisms. 
 Chemotherapy and radiotherapy are named systemic therapies since 
they influence the entire region they are administered to as opposed to targeted 
therapies that mainly influence cancerous cells with the specific genetic trait 
that the drug is designed against. The variety of resistance mechanisms to 
these therapies require the identification of resistance mechanisms on an 
individual basis and adaptation of targeted treatment regimens that can 
neutralize the source of drug insensitivity.
Targeted therapies and drug resistance 
As mentioned earlier, chemotherapy and radiotherapy are specifically toxic to 
actively cycling cells. Although unlimited reproduction is one of the hallmarks 
of cancer cells [55], there are also healthy tissues in the body where actively 
cycling cells reside such as blood, intestines, epithelial tissue in the mouth and 
hair follicles. Therefore, these tissues also suffer from the cytotoxic effects of 
chemo and radiotherapy, resulting in severe side effects. Unlike these therapies, 
targeted therapies are designed against a specific genetic trait that is exclusively 
found in the cancer cells. Because these drugs target a particular vulnerability 
of a certain kind of cancer, they generally cause less toxicity. For example, 
some breast cancers that express abundant levels of human epidermal growth 
factor receptor (HER2) or estrogen receptor (ER) generally rely on signaling via 
these receptors for their survival. Inhibiting these receptors by an antibody 
against HER2 like trastuzumab (Herceptin®) or by an ER-antagonist like 
tamoxifen generates impressive results in hormone receptor-positive breast 
cancer treatment [56-59]. Similarly, there are several tyrosine kinase inhibitors 
(TKI) that target kinases on which cancer cells rely for survival. Imatinib 
inhibits the non-receptor tyrosine kinases (TK) BCR-ABL and c-KIT, and the 
receptor TK PDGFRA. This inhibitor proved to be very effective especially in 
chronic myeloid leukemia (CML)  [60, 61], acute lymphoblastic leukemia (ALL) 
[62-64], and gastrointestinal stromal tumor (GIST) [65] patients. Unfortunately, 
some cancers develop resistance even against the most effective drugs. Gorre 
et al. and Hochhaus et al. found that more than half of the CML patients in 
their trials acquired resistance to imatinib through (multiple) point mutations 
in BCR-ABL that consequently caused a conformational change in the kinase, 
circumventing the inhibitory effect of the drug [66, 67]. Other mechanisms of 
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resistance include the acquisition of a second Philadelphia (Ph) chromosome 
(the chromosome formed as a result of the t(9;22)(q34;q11) translocation that 
generates the BCR-ABL fusion gene product) and overexpression of the BCR-
ABL transcript [67]. Similarly, mutations in c-Kit or PDGFR have been found 
to be correlated with resistance to imatinib in GIST patients [68-70]. Another 
prominent example of acquired resistance is the EGFRT790M mutation that 
confers resistance to tyrosine kinase inhibitors (TKI) such as gefitinib and 
erlotinib in non-small cell lung cancer (NSCLC)  [71, 72]. About 10% of NSCLC 
patients harbor a gain-of-function mutation on the EGFR gene that renders 
their tumors sensitive to EGFR inhibitor treatment, inducing a dramatic 
response to therapy [73]. However, the disease almost always recurs [74] and a 
secondary mutation, T790M, is detected in 50% of the relapsed patients [75, 76].
 Finally, inhibiting an oncogenic driver pathway does not always 
result in a tumor response. For instance, although melanomas with BRAFV600E 
mutation respond very well to the BRAF inhibitor vemurafenib, colon cancer 
cells with the same mutation fail to show a similar sensitivity. This is because 
in colon cancer cells, the EGFR pathway is rapidly activated in response to 
vemurafenib exposure and the survival signals are maintained; melanoma 
cells do not express sufficient levels of EGFR due to their neural-crest origin 
[77].
 As effective as targeted therapies seem at first, drug resistance remains 
a recurrent problem. Extensive research is being carried out in order to identify 
and exploit resistance mechanisms.
Strategies to overcome drug resistance in cancer treatment
It is clear that there is no single cure to any type of cancer since there are always 
patients suffering from treatment resistance, whether intrinsic or acquired. 
However, resistance mechanisms can also be vulnerabilities of tumors. From 
a clinical perspective, overexpressed DDR components, drug transporters 
and metabolic enzymes that inactivate drugs, activated parallel pathways, 
common activating mutations like the EGFR T790M can all be perceived as 
secondary drug targets. Uncovering these mechanisms is important to battle 
resistance, for example by discovering new drug delivery methods against 
MDR or combination therapies against additional survival pathways. Recently, 
smart nano-particles were designed that can specifically and efficiently 
15 
Ch
ap
te
r 1
deliver chemotherapeutic agents to the cancer cells evading drug efflux [78, 79]. 
Furthermore, combining vemurafenib with an EGFR inhibitor in BRAF mutant 
colon cancer cells, selumetinib (MEK inhibitor) with a dual EGFR-ERBB2 
inhibitor in KRAS mutant colon and lung cancer cells, a MEK inhibitor with 
a ROCK inhibitor in NRAS mutant melanoma cells can also cause increased 
tumor cell killing [77, 80, 81]. However, most of these strategies are developed 
in vitro and are still pending clinical confirmation. Additionally, several 
second and third generation inhibitors are developed to target the acquired 
mutations that confer resistance to the first generation drugs. For instance, 
afatinib, a second generation inhibitor of EGFR, EGFRT790M and HER2, extends 
the progression-free survival of erlotinib/gefitinib-resistant NSCLC patients 
[82] and, in combination with cetuximab, results in tumor regression in EGFR-
mutant lung cancer [83]. However, it did not take long for acquired resistance 
to the second generation EGFR inhibitors to emerge. After promising initial 
results, several third generation EGFR inhibitors with enhanced potency 
for constitutively active EGFR and EGFRT790M are currently being assessed 
in clinical trials [84, 85]. Similarly, as effective as it was as the first tyrosine 
kinase inhibitor in CML treatment, as discussed above, tumors eventually 
developed resistance against imatinib via various mechanisms. The next 
generation BCR-ABL inhibitors bosutinib, nilotinib and dasatinib target several 
kinases including c-Kit, PGGFR, ABL, EPHB4 and Src as well as numerous 
mutant forms of BCR-ABL [86-89]. However, these too were ineffective against 
the T315I mutation on BCR-ABL, a point mutation that causes the strongest 
resistance against imatinib and all approved second-generation BCR-ABL 
inhibitors [90]. Most recently, ponatinib was developed specifically to target 
T315I mutation [91] and showed unprecedented response rates in clinical trials 
[92-94]. Inevitably, additional primary or secondary mutations influence the 
response to ponatinib treatment too [95, 96].
 Another relatively recent strategy is to exploit so-called non-oncogenic 
dependencies of cancer cells. Cancer cells can be addicted to intrinsic and 
extrinsic non-mutated pathways that function as they do in normal cells 
and tissues, providing no obvious advantage to the tumor. Nonetheless, like 
oncogenic pathways, these too can be crucial for tumor maintenance [97]. 
Additional targeting of such pathways impairs tumor growth by sensitizing the 
cancer cells to treatment or acting synergistically with other therapies, driving 
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synthetic lethality. For instance, DDR is crucial for tumor maintenance, since 
cancer cells suffer from severe genomic instability and replication stress [98]. 
Targeting cell cycle checkpoints in combination with DNA damaging agents 
such as chemotherapy and radiotherapy increases the sensitivity of cancer 
cells to therapy [99]. Similarly, angiogenesis is an extrinsic process tumors 
heavily rely on for oxygen and nutrient delivery to support their constant 
growth. Although further research and optimization are warranted, combining 
conventional therapies with anti-angiogenic agents provided promising 
results [100]. 
 A crucial support system for tumors is the extracellular matrix (ECM), 
which is composed of secreted factors such as growth factors and chemokines, 
tumor infiltrating cells, and cell adhesion molecules such as integrins, 
cadherins and selectins. Accumulating evidence demonstrates that most of 
these components have a tumor-protective role against drugs [101-103]. For 
instance, hepatocyte growth factor (HGF) has been shown to confer resistance 
to RAF inhibitors in BRAF mutant melanoma, colon cancer and glioblastoma 
cells [104, 105]. Also in a clinical setting, serum levels of HGF and epiregulin 
(EREG) were correlated with anti-EGFR therapy resistance in colorectal cancer 
[106]. It therefore is also crucial for anti-cancer therapy to better understand the 
role of tumor microenvironment. Finally, as demonstrated by several genetic 
screens, synthetic lethality can be achieved also by combined inhibition of 
non-oncogenes  [81, 107, 108]. 
 Last but not least, an exciting breakthrough in cancer research came 
from the immunotherapy field in the form of ‘immune checkpoint therapy’. 
Evasion of immune surveillance is now considered one of the hallmarks 
of cancer [98] and harnessing the immune system against tumors is a 
revolutionary strategy. As the very complex mechanisms of its regulation are 
being unraveled, components of the immune system can be better utilized 
in anti-cancer therapy. By downregulation of co-stimulatory molecules 
or upregulation of co-inhibitory ones, cancer cells can render themselves 
undetectable by, or resistant against, the immune system [109]. Recently, two 
strategies have been developed that successfully lead to tumor eradication by 
unleashing active T cells on the cancer cells. First, cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) receptor was identified as a factor that competes 
with CD28 to bind to B7 ligands on antigen presenting cells (APCs), resulting 
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in inactivation of active T-cells [110, 111]. CTLA-4 inhibition therefore allows for 
prolonged activation of T cells leading to cancer cell clearance by the immune 
system [112]. Ipilimumab, an anti-CTLA-4 antibody, achieved positive results 
in the clinic as monotherapy or in combination with other agents [113-116]. 
More recently, programmed death 1 (PD1) – programmed death ligand 1 (PD-L1) 
receptor-ligand interaction was found to have a similar impact on T cells as 
CTLA-4–B7 binding. PD-1 and PD-L1 inhibition by monoclonal antibodies has 
been an intense focus of research, leading to very promising clinical outcomes 
especially in melanoma, NSCLC, renal cell and ovarian cancers [117-122].
 Developing customized treatment methods based on the identification 
of driver mutations has proven to be a successful intervention strategy for 
a subset of tumors [123-125]. Although it will conceivably be possible in the 
near future, at the moment we are lacking a cost-effective and sufficiently fast 
technology to analyze every tumor, whether primary or metastasis, to tailor an 
effective treatment regimen for cancer patients. Tumors are very complex, often 
heterogeneous cell structures that are able to manipulate their surrounding to 
sustain their own survival. Non-oncogene addiction shows that cancer cell 
killing is possible by targeting the support system of tumors, independently 
from what driver mutations they might have. Despite the exciting success 
rates of immunotherapeutic strategies, which also have the great advantage of 
being driver mutation-independent, differential responses, insensitivity and 
resistance to therapy are persistent issues warranting further investigation of 
these mechanisms.
Metastasis
Metastasis, literally meaning ‘removal’ or ‘change’ in Greek, refers to cancer 
cells appearing at different locations than the primary tumor, thereby 
forming secondary tumors. It is mechanistically a very dynamic and complex 
process that is only partially uncovered, mostly not in clinically applicable 
settings. Metastasizing cells are thought to undergo EMT, a developmental 
program that gives epithelial cells temporary mesenchymal properties such 
as motility and allows them to break loose from the tissue they are attached 
to. This program, also utilized during wound healing, is thought to be the 
major mechanism of metastasis [126]. However, metastasis to a distant site 
requires a lot more than just cell detachment [127].  Metastatic cancer cells 
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assume a spindle-like morphology rather than a cuboidal one. They are able 
to digest through the basement membrane and join the circulation. After 
surviving the mechanical stress inflicted by the flowing blood or lymph fluid, 
they attach to and migrate though the endothelium to seed into a secondary 
organ. These cells then undergo mesenchymal-epithelial transition (MET) 
to regain their epithelial properties and grow as a tumor. Each of these steps 
requires the activation or inactivation of a different set of genes. There are 
some commonly used markers to determine whether a cell is in an epithelial 
or a mesenchymal state. Apical-basal polarity and cell-cell adhesions are 
strong indications of epithelial phenotype [128]. E-cadherin and catenins are 
used as epithelial markers, whereas β-catenin, N-cadherin and vimentin are 
used as mesenchymal markers. However, these markers are not absolute. For 
instance, breast cancer cells lose their metastatic capacity and become more 
epithelial than mesenchymal, as shown by an increase in E-cadherin and 
γ-catenin expression, whereas a decrease in the tested mesenchymal markers 
was not detected [129]. This and other similar observations [106] suggest that 
cells might undergo a partial EMT, and epithelial and mesenchymal states 
are not necessarily black and white with regard to gene expression patterns 
and migratory capacity. Instead, EMT should rather be seen as a large grey 
area where the cells dynamically gain and loose properties that make them 
epithelial or mesenchymal to various extents.  
 Not surprisingly, regulation of such a gradient is very sophisticated. 
Numerous studies were designed to identify EMT-associated gene classifiers. 
Transcription factor families of Snail, Zeb, Twist [130], and upstream signaling 
pathways like TGFβ [131], Notch, Hedgehog, Wnt, TrkB  [132, 133] are known 
master regulators of EMT. Recent data suggest that Fra-1 is also among 
these master regulators since it is found to modulate EMT genes in certain 
contexts [129, 134-138]. Although EMT is perceived to be pro-oncogenic and 
pro-metastatic [139], it has recently come to light that TGFβ-induced EMT can 
also have a tumor-suppressive role and result in apoptosis depending on cell 
lineage [140].
 The physiological occurrence of EMT in cancer, and its relevance to 
disease progression have long been under debate. The rapidity of the changes, 
difficulties in determining the timing of these events and particularly its 
reversibility make it almost impossible to detect cells in transition in clinical 
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settings. Most histological analyses on primary tumors and metastases are 
based on the presence or absence of the most commonly used EMT markers 
such as E-cadherin, N-cadherin and vimentin. However, as discussed earlier, 
the transient and dynamic nature of EMT combined with the proposition that 
there is no marker that guarantees positive identification of cells undergoing 
EMT create a challenge to detect transitioning cells in vivo. Furthermore, 
there is evidence that some tumors still metastasize once key events that are 
required for EMT are blocked [141-143]. However, some of these studies focused 
only on the expression of EMT genes and not on the cellular localization of 
the gene products. The metastatic phenotype is closely linked to cellular 
morphology, which is regulated not only by changes in the expression but also 
by changes in the localization of cell junction proteins such as E-cadherin and 
β-catenin. It therefore is crucial to also consider the functional implications of 
manipulating gene expression. Additionally, since all details on the metastatic 
cascade and EMT are not fully discovered, it is possible that a yet unknown 
or a compensatory mechanism mediates metastasis under such experimental 
conditions. 
 On the other hand, there are a substantial number of studies 
correlating the expression levels of EMT markers with disease progression and 
aggressiveness [144-147]. More and more in vivo studies are being designed 
to prove that EMT is a clinically relevant phenomenon and targeting EMT 
is a viable therapeutic option. With the development of intravital imaging, 
in vivo real-time monitoring of some tumor types is possible. Recently, two 
studies utilized this method to show that EMT occurs in spontaneous mouse 
mammary tumors [148, 149]. Zhao et al. found that the population of cells that 
have undergone EMT is heterogeneous and characterized three subpopulations 
of EMT cells: silent, migratory and fibroblast-like. They also showed that 
the c-Met inhibitor Cabozantinib, known to inhibit metastasis, functions by 
causing a larger silent EMT population and smaller migratory and fibroblast-
like populations, substantially limiting tumor growth [148]. Beerling et al., 
on the other hand, focused on the plasticity of EMT cells and demonstrated 
that there are E-cadherinlow and E-cadherinhigh states of mouse mammary 
cells, which are reversible within a few cell divisions. Interestingly, their data 
support the notion that EMT is required for migration but not for intravasation 
since they find cells in both states in the circulation [149]. Metastasis can occur 
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at very early stages of tumor progression [150]. In some cases, it is thought to 
occur years before the primary tumor is diagnosed [151]. These high-resolution 
imaging studies are crucial to precisely distinguish the steps of the metastatic 
cascade and identify potential targets for therapy.  
EMT, stemness and therapy resistance
Changes in the cell during EMT are not restricted to cellular morphology and the 
initiation of a metastasis-related transcriptional program. Transitioning cells 
also acquire stem-like characteristics based on the changes observed in known 
cancer stem cell markers. For instance, transformed mammary epithelial cells 
assume a stem cell-associated CD44high/CD24low profile accompanied with an 
increase in the EMT markers Sail and Twist [152]. Similarly, CD44high/CD24low 
oral squamous cell carcinoma cells display lower E-cadherin expression as 
well as a low E-cadherin to vimentin ratio as compared with CD44low/CD24high 
population [153]. Also, changes in known factors important both for EMT-
induced metastasis and for stem cell maintenance such as TGFβ, Notch, Wnt, 
Hedgehog [154] point to a close link between EMT and induction of a stem cell 
phenotype. Finally, regulation of important players in stem cell maintenance 
such as miRNA200 family and BMI by prominent EMT markers like ZEB1 and 
Twist implies that stemness is a trait included in the EMT package [155, 156].
 Because cancer stem cells are known to be therapy-resistant [157], 
stem-like characteristics gained by the EMT program are thought to generate 
cancer cells insensitive to therapy mediated by previously discussed 
resistance mechanisms like overexpression of drug transporters [158] and 
apoptosis evasion [159-161]. Since the early 90s, numerous studies proved that 
EMT is associated with resistance to radiation and chemotherapy including 
the most common agents doxorubicin, paclitaxel, gemcitabine, 5-fluorouracil, 
cisplatin and cyclophosphamide  [143, 162-165]. EMT is also involved in 
resistance to targeted therapies. Vemurafenib resistance in melanoma and 
gefitinib resistance in NSCLC have been shown to be caused by EMT [166-168]. 
Importantly, cells could be sensitized to therapy upon reversion of the EMT 
phenotype [168, 169]. 
 While the correlation between EMT and drug resistance is well-
established, a causal link between EMT-induced stemness and drug resistance 
has only recently been established [153, 168, 170]. Two independent reports 
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claim that stem cell and EMT characteristics co-exist in cisplatin-resistant 
oral squamous cell carcinoma cells as judged by: 1- an increase in stem cell-
associated molecules CD44, Oct4, c-Myc; 2- a decrease in the differentiation 
marker involucrin; 3- bigger and more non-adherent sphere formation as 
an indicator of self-renewal capacity; 4- lower levels of E-cadherin and 5- 
morphological changes that point to EMT [153, 171]. Similarly, chemotherapy-
resistant ovarian cancer cells not only harbor several EMT traits, but also 
carry stem cell properties including non-adherent sphere formation and 
expression of the common stem cell markers BMI, CD44, and NANOG, all of 
which is suggested to be orchestrated by FOXM1 [172]. Finally, Richard et al. 
showed an inverse correlation between Zeb1 and MITF in melanoma where 
Zeb1high/MITFlow cells were resistant to vemurafenib treatment in vitro and 
in vivo. Moreover, Zeb1 overexpression induces a stem-like phenotype while 
Zeb1 downregulation induces differentiation and sensitizes melanoma cells to 
Vemurafenib [168].  
 Accumulating findings make a strong connection between the most 
threatening aspects of cancer: EMT, cancer stem cells, and therapy resistance. 
Extensive research focuses on each of these topics individually as well as 
their functional interactions with each other. Recent evidence suggests that 
all three are interconnected, rendering a subpopulation of cancer cells almost 
invincible. On the other hand, this connection could give us a unique advantage 
and allow us to impair EMT, stemness and therapy resistance at the same time. 
Concluding remarks
In the modern age, science and technology rapidly improve and go hand in 
hand with the development of groundbreaking therapies in the battle against 
cancer. Scientists promptly tackle every challenge cancer cells present 
and newly developed drugs are actively evaluated by clinicians. Yet, almost 
invariably there are tumors that do not fully respond or relapse owing to 
the resistance mechanisms discussed above. Although second and third 
generation drugs that target drug resistant cancer cells prove beneficial in 
clinical trials, eventual resistance to these is also expected, explaining why 
complete clinical eradication of disease is a great challenge. Nonetheless, new 
and rare vulnerabilities in cancer cells are constantly discovered by (functional) 
genomic, proteomic and metabolomics efforts, paving the way towards 
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Abstract
Breast cancer is the second most common cause of cancer-related deaths 
worldwide among women. Despite several therapeutic options, 15% of breast 
cancer patients succumb to the disease owing to tumor relapse and acquired 
therapy resistance. Particularly triple-negative breast cancer (TNBC), for which 
treatment options are limited owing to the lack of a common vulnerability that 
can be exploited by targeted approaches, is a challenge. We have previously 
shown that tumor cells have different requirements for growth in vivo than in 
vitro. Therefore, to discover novel drug targets for TNBC, we performed parallel 
in vivo and in vitro genetic shRNA dropout screens. We identified several 
potential drug targets that were more required for tumor growth in vivo than 
in vitro. By using combinatorial treatments with pharmacologic inhibitors 
acting on a subset of these candidates, we identified a synergistic interaction 
between EGFR and ROCK inhibitors, which effectively reduced TNBC cell 
growth by inducing cell cycle arrest. These results illustrate the power of in 
vivo genetic screens and warrant further validation of EGFR and ROCK as 
combined pharmacologic targets for breast cancer.  
Introduction
Breast cancer is the most commonly diagnosed cancer and the second most 
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common cause of cancer-related deaths among women worldwide [1]. Although 
several treatment options are available, 15% of breast cancer patients succumb 
eventually, due to relapse and/or distant metastases that are associated 
with acquired resistance to current therapies. Especially triple negative 
breast cancer (TNBC), which is named so due to the absence of ER, PR and 
HER2 receptors and constitute 15-20% of all breast cancers, has proven to be 
challenging owing to the lack of a common vulnerability that can be exploited 
by targeted approaches.
 Although tumors generally have a high number of mutations, genomic 
instability and chromosomal aberrations [2], only a fraction of these events 
contributes to tumor formation and progression [3]. In the last decade, there 
have been several sequencing efforts to unfold the mutational landscape of 
tumors, to identify driver mutations and develop targeted therapies [3-7]. BRAF 
mutations in melanoma [8, 9] or EGFR and ALK mutations in lung cancer [10, 
11] are some examples of such activated oncogenes that tumors are addicted to 
and hence, represent attractive therapeutic targets. In the case of breast cancer, 
targeted endocrine therapies can be used for ER+ and HER2+ tumors, but are 
ineffective for the triple negative subtype due to the absence of expression of 
hormone receptors. In fact, TNBC lacks such oncogene signatures that would 
allow tumors to be sub-grouped and specifically targeted. Aside from p53 
mutations (80%), the most common genetic aberration in TNBC is in PI3K, which 
occurs in 9% of the cases [6]. Additionally, a set of TNBC displays targetable 
BRCA-like clinical and pathological features, which render these tumors 
sensitive to PARP inhibition [12]. More recently, a detailed analysis of somatic 
alterations in breast cancer samples revealed a number of mutations that are 
specific to the basal-like breast cancer subtype [13]. However, a significant 
proportion of patients are still dependent on chemotherapeutic approaches.
 Although the majority of TNBC tumors initially respond to conventional 
chemotherapy, TNBC patients still have a poor prognosis [14, 15]. Numerous 
clinical studies have been conducted in recent years to assess the effectivity of 
targeted agents such as PARP, EGFR and VEGF inhibitors in different settings. 
These efforts, however, either failed to significantly improve patient survival 
or were inconclusive [16, 17]. It therefore is crucial and urgent to identify novel 
therapeutic targets to treat TNBC.
 At least as important as oncogene addiction is the concept of non-
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oncogene addiction or essentiality, reflecting that genetically unaltered and 
normally functioning pathways (which would not be identified by sequencing) 
can also be critical to a tumor’s maintenance [18]. This phenomenon in 
principle greatly expands the spectrum of potential drug targets for cancer 
treatment. In line with this, and because TNBC lacks genetically obvious 
common vulnerabilities, we sought to identify novel drug targets by 
performing unbiased genetic screening, which is a powerful tool that has 
been widely employed in cancer research to search for novel targets for 
therapy [19]. Since in vitro screens typically fail to cover crucial components 
that contribute to tumor progression such as stromal interactions, immune 
system, and vascular structure, in vivo screens have become a more favorable 
approach [20, 21]. We recently uncovered a synthetic lethal effect of hypoxia 
and DNA damage response inhibition by a similar approach [22], illustrating 
the power of performing such screens in an in vivo setting. Therefore, we set 
out to carry out parallel in vivo and in vitro loss-of-function shRNA screens 
for the identification of novel targets for breast cancer. Identified targets were 
subsequently interrogated with pharmacological inhibitors using combination 
screens to identify effective, synergistic combinations.
Results
Screening for kinases that are required for tumor growth in vivo
In order to establish a physiologically relevant model and identify more 
clinically realistic targets, we performed an in vivo screen with a parallel 
in vitro counterpart. This system allowed us to specifically uncover those 
genes that are more critical for tumor survival in vivo compared to in vitro 
[22]. Because tumors highly rely on kinase pathways and new therapies 
targeting kinases are being widely explored [27], we chose to use a kinome 
library derived from the genome-wide TRC library [28] and composed of ~3000 
shRNAs targeting ~500 kinases [22, 29]. Two TNBC cell lines, HCC1806 and 
MDA-MB-231, were transduced with the kinome library in four pools (Figure 
1A). After three days of antibiotic selection for successful transduction and 
expansion, reference samples were collected. The remaining cells were 
either injected into the mammary fat pads of six NSG mice (in vivo screen) or 
seeded in tissue culture dishes in six replicates (in vitro screen). Tumors were 
harvested once they reached 50-100mm3 and the cultured cells were harvested 
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after two expansions. The presence of each shRNA in reference, in vitro and in 
vivo samples was quantified using genomic DNA extraction followed by PCR 
amplification and deep sequencing. 
 Before hit calling, we performed several quality control analyses to 
confirm that the data generated from the screens was sufficiently robust for 
negative selection analyses. First, quantification of the shRNAs present in 
tumors and in in vitro samples showed that the complexity of the library was 
maintained throughout the experiment, as we could detect approximately 
3000 unique shRNAs in the references, cultured cells and tumor samples. 
Importantly, the majority of these shRNAs were shared amongst all sample 
groups. Specifically, 85% were shared between the cultured cells and tumors. 
These findings indicate that the complexity of the library was well maintained; 
this allowed the identification of shRNAs that were lost due to functional 
selection of a specific shRNA rather than random selection of shRNAs as a 
result of sampling due to clonal expansion (Figure 1B, Suppl. Fig. 1A). 
 We observed a high correlation of shRNAs between biological 
replicates (Figure 1C, Suppl. Fig. 1B). Unsupervised clustering analysis showed 
that, for each experimental group, all biological replicates clustered into one 
branch, suggesting that the abundance of shRNAs present in these replicates 
is reproducible and supporting the robustness of the system (Figure 1D, Suppl. 
Fig. 1C). 
Identification of in vivo-specific targets 
In vivo-specific hits were identified based on the following criteria: 1) an shRNA 
should be significantly depleted (p<0.01) and have an effect size of at least 
30% in tumors compared to in vitro samples; 2) a gene should be represented 
with at least two shRNAs in the screen; 3) an shRNA for a selected gene in (2) 
should not be enriched more than 20% in in vitro samples compared to the 
references; and 4) an shRNA for a selected gene in (2) should not be enriched in 
tumor samples compared to the references. For the genes targeted by shRNAs 
fulfilling these criteria, we compared the hit lists from both HCT1806 and 
MDA-MB-231 screens to finally generate a list composed of genes identified 
in both screens, corresponding to the fifth selection criterion (Figure 2, Table 
1). The hit list comprised receptor tyrosine kinases (EGFR, MERTK, IGF1R), 
intracellular signal transducers (AKT1, MET, mTOR, RSK2), cytoskeletal 
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Figure 1. Screening for kinases that are required for tumor growth in vivo. A. Set-up of the screens. 
HCC1806 and MDA231 cells were transduced with the kinome library in four pools with lentivirus 
at an MOI<0.2. After three days of puromycin selection, reference samples were collected and the 
remainder of the cells were either transplanted into the mammary fat pads of six NSG mice or 
seeded into six independent dishes for the in vitro screen. B. The complexity of the library was 
retained among all groups in the HCC1806 cell screen. Bars show the average number of shRNAs 
per biological group. Of the 2997 shRNAs detected in the reference samples, 2882 and 2710 were also 
found in cultured cells and tumors, respectively. Dark parts of the bars represent the shared shRNAs 
among the biological replicates within a group. 96% of the shRNAs were commonly found among the 
cultured cells while 90% were common among the tumors. C. Biological replicates correlated well 
with each other. A representative example from each sample group is shown. Every dot represents 
an shRNA. X- and y-axis show the abundance of shRNAs. D. Euclidean distance heat map showing 
the degree of similarity between all samples. All biological replicates in a sample group cluster 
together. 
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regulators (FAK, ROCK1), and some functionally under-investigated genes 
(NEK5, SIK2). 
Uncovering synergistic combinations by pharmacologically targeting 
hits
By using the kinome library for our screens, we wished to take advantage of the 
fact that kinases are relatively easy to target pharmacologically, allowing us to 
translate our results to a pre-clinical setting. Notably, previous experiences on 
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Figure 2. Identification of in vivo-specific targets. Comparison of tumors to cultured cells by DESeq 
analysis in A. HCC1806 and B. MDA-MB-231 cells. X-axis shows the average abundance of each 
shRNA across all samples on log10 scale. Y-axis shows the fold change of each hairpin in tumors 
compared to the cultured cells in log2 scale. Common hits identified based on the criteria are color-
coded.
targeted therapy approaches have shown that most single-agent treatments 
fail to offer a long-term solution as tumors commonly recur because of drug 
resistance [30]. Moreover, an effective combination of two or more targeted 
agents in TNBC is lacking. We therefore sought to identify synergistic 
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        HCC1806 
        
         TARGETS ROCK EGFR mTOR (1) mTOR (2) AKT FAK FGFR MET 
ROCK 0.74 4.25 0.82 0.16 0.97 0.13 4.61 1.01 
EGFR   0.58 0.93 2.38 1.91 2.25 0.92 0.19 
mTOR (1)     0.74 2.24 7.63 0.67 0.28 1.7 
mTOR (2)       1.97 2.51 2.05 0.11 4.16 
AKT         1.16 0.23 0.14 0.16 
FAK           0.18 0 0.93 
FGFR             0.3 1.54 
MET               1.59 
	  
	  
 
	  
  	  
 
 	  
	   	  	   	   	   	   	   	   	   	   	   	   	   	   1                       max 
 
        MDA231 
        
         TARGETS ROCK EGFR mTOR (1) mTOR (2) AKT FAK FGFR MET 
ROCK 0.33 3.16 0.63 0.5 0.71 0 0.73 0 
EGFR   0.93 0.29 0.14 0.1 0 0.11 1.12 
mTOR (1)     0.12 1.37 2.97 0.26 0.14 0.07 
mTOR (2)       0.99 1.7 0.66 0.42 0.69 
AKT         0.33 0.46 0.42 0.13 
FAK           0.18 0.13 0.02 
FGFR             0.63 0.01 
MET               0.83 
	  
	  
 
	  
  	  
 
 	  
	   	  	   	   	   	   	   	   	   	   	   	   	   	   1                 max 
A.
B.
Table2. Synergy scores of combination treatments in A. HCC1806 and B. MDA-MB-231 cells. The 
synergy scores of all combination treatments, including self-self combinations are shown. Because 
scores >1 was considered synergistic, the heat map grades scores between 1 and the maximum score 
in the table. 
MDA-MB-231 HCC1806 common
AKT1 2 2 0
EGFR 2 3 1
mTOR 2 5 2
IGF1R 2 2 1
MERTK 2 2 1
MET 4 3 1
NEK5 3 2 2
FAK 5 4 1
ROCK1 2 2 0
RSK2 2 2 1
SIK2 2 2 2
number of shRNAs
Table 1. Common hits from the two in vivo screens. Columns indicate how many shRNAs for the 
corresponding gene were found in each screen and how many of these were the exact same shRNA.
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combinations between our hits in both MDA-MB-231 and HCC1806 cells using 
an in vitro drug matrix setting. It is important to point out here that the in 
vivo-in vitro differences observed are not absolute but rather reflect sliding 
windows. Therefore, certainly when combining the inhibition of multiple 
targets, we expected to see significant effects in in vitro assays also, aiming to 
find potential new treatment regimens. 
 We selected the set of genes from our hit list against which commercially 
inhibitors are available that are either already FDA-approved or are being 
evaluated in clinical trials for different types of cancer and other diseases. 
These were combined with each other in 5x5 dose matrices. Establishing 
single-treatment dose response curves with each matrix allowed us to compare 
combined treatments with the expected additive effects of singe treatments 
(Suppl. Fig. 2). The results are presented as synergy scores after calculating the 
differences between the expected and the actual effects (Table 2). Scores >1 are 
considered synergistic, provided that the self-self combination of each drug 
has a lower score than the combination score. 
 To rule out cell line-specific effects, we selected combinations 
that showed synergistic effects in both TNBC cell lines tested. One such 
combination, two mTOR inhibitors (AZD8055 and Everolimus), was excluded 
from the analysis because both target the same kinase. Within the same 
pathway, we observed synergy when combining AZD8055 or Everolimus with 
the AKT inhibitor MK2206. This finding was reassuring, since synergistic 
effects of AKT and mTOR inhibition have previously been reported for other 
cancer types [31-34]. With this experimental approach we observed a highly 
synergistic effect when combining the EGFR inhibitor Gefitinib (EGFRi) with 
the ROCK inhibitor GSK269962A (ROCKi) (Suppl. Fig. 3). Based on these results, 
and on the results of the shRNA screen on the same cell lines, we focused on 
this combination for further investigation of potential therapeutic applications 
in TNBC. 
EGFR and ROCK1 depletion impairs TNBC growth
We confirmed that the different shRNAs against EGFR and ROCK1 that scored 
as hits in the screens reproducibly caused effects similar to those seen in 
the screen. The identification of multiple unique shRNAs for both EGFR and 
ROCK1 rules out a possible off-target effect. To compare this validation with 
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the screening results, we studied in more detail the shRNA distribution in 
each experimental group of the in vitro and in vivo screens. As expected, 
we observed a more pronounced loss of shRNAs targeting EGFR and ROCK1 
in tumors as compared to both the references and the in vitro cultured cells 
(Figure 3A, Suppl. Fig. 3A). We then transduced TNBC cell lines with the 
individual shRNAs against EGFR and ROCK1 and showed efficient silencing of 
the target genes (Suppl. Fig. 3B). Finally, we evaluated the effect of EGFR and 
ROCK silencing on tumor cell viability in vitro and growth in vivo. In vitro, cell 
proliferation followed the same pattern predicted by the screen results: knock 
down of either gene showed little effect on the cell lines, with the exception of 
hairpin #2 targeting ROCK1 in HCC1806 cells (Figure 3B, Suppl. Fig. 3C). As all 
hairpins for ROCK1 successfully depleted the protein, we could not determine 
whether this reflected a difference in remaining ROCK1 levels (Suppl. Fig. 3B). 
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Figure 3. EGFR and ROCK1 depletion impairs TNBC 
growth. A. shRNA read counts of the hairpins in the 
reference, cultured cells (invitro) and tumor samples 
as found in the HCC1806 screen. B. HCC1806 cells 
were transduced with lentiviral constructs against 
EGFR and ROCK that were identified as hits in the 
screen. After puromycin selection, 0.3*105 cells 
were seeded on 6-well plates. Cells were stained 
with crystal violet after six days. C. HCC1806 cells 
transduced with lentiviral constructs against 
luciferase, EGFR and ROCK were orthotopically 
injected into the 4th mammary fad pad of NSG mice. 
Tumors were measured manually by a caliper and 
tumor volume was calculated by the formula a*b2/2. 
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In vivo, on the contrary, silencing of either ROCK1 or EGFR impaired growth of 
HCC1806 xenografts (Figure 3C).
Combined EGFR and ROCK inhibition effectively blocks proliferation of 
TNBC cells
Because the synergistic effect of EGFR and ROCK inhibitor combination 
was identified in 72-hour dose-response assays, we performed longer-term 
experiments and confirmed that this combination has a major impact on 
the expansion of both MDA-MB-231 and HCC1806 cells while single inhibitor 
treatment only mildly impairs growth (Figure 4A). The effect of the inhibitors 
on EGFR and ROCK signaling was confirmed by analyzing EGFR, AKT and 
MYPT phosphorylation status upon EGFR and ROCK inhibitor treatments, 
respectively (Suppl. Fig. 4A). In addition, we found similar results with other 
inhibitors of EGFR and ROCK, Afatinib and Fasudil, respectively, suggesting 
that this is indeed a target-specific and not a compound-specific effect (Suppl. 
Fig. 4B). Moreover, double knockdown of EGFR and ROCK impaired the growth 
of HCC1806 cells, further supporting specificity of the effect of the inhibitors 
combination (Suppl. Fig. 4C). 
 The growth inhibition caused by EGFRi and ROCKi combination 
was not limited to MDA-MB-231 and HCC1806 cells. We observed substantial 
growth impairment in a panel of another six TNBC cell lines also (Figure 4B). 
Furthermore, compared to each inhibitor alone, the inhibitory growth effect of 
the combination on orthotopic tumors formed by HCC1806 cells was enhanced, 
however did not reach statistical significance (Figure 4C). The combinatorial 
effect of EGFR and ROCK inhibition was independent of the expression 
levels of EGFR and ROCK proteins or of the phospho-EGFR or phospho-MYPT 
(downstream target of ROCK) levels (Suppl Fig. 4D). This proof-of-concept result 
warrants further validation and optimization of the combined pharmacologic 
targeting of EGFR and ROCK for TNBC. 
Combined EGFR and ROCK inhibition causes cell cycle arrest
We next sought to identify the mechanism by which combined inhibition 
of EGFR and ROCK impairs cell growth. Consistent with the involvement of 
ROCK in the regulation of cell shape and movement [35], we observed major 
changes in cell morphology upon ROCK inhibitor treatment (Suppl. Fig. 5A). 
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Figure 4. Combined EGFR and ROCK inhibition effectively blocks proliferation of TNBC cells. A. 0.1*105 
cells were seeded onto 12-well plates. Drugs were added one day after seeding and refreshed at the 
third day. MDA-MB-231 cells were treated with 20μM Gefitinib (EGFRi), 4.8μM GSK269962A (ROCKi) 
or the combination. HCC1806 cells were treated with 8.4μM EGFRi, 2.4μM ROCKi or the combination. 
Same doses were used for the combination treatments. Cells were stained with crystal violet six 
days after treatment. B. EGFRi-ROCKi combination has enhanced toxicity also on other TNBC cell 
lines. EGFRi concentration for Cal51, Cal120, Hs578T, HCC38, BT549 and LM2 cells was 20μM. ROCKi 
concentration for Cal51 cells was 12μM, for Cal120 cells was 30μM, for Hs578T cells 1.2μM, for HCC38 
cells 12μM, for BT549 cells 8μM, for LM2 cells 4.8μM. C. HCC1806 cells were orthotopically injected 
into the 4th mammary fat pad of NSG mice. Starting from one day after inoculation, mice were 
orally treated six times a week with DMSO-containing vehicle, 90mg/kg EGFRi, 10mg/kg ROCKi, or 
EGFRi+ROCKi. Tumors were measured twice weekly and the tumor volumes were calculated by the 
formula a*b2/2.
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Cells became flattened, larger and had several protrusions. When EGFR and 
ROCK inhibitors were combined, the remaining cells acquired neuron-like 
long extensions. 
 Since we found very few cells surviving the combination treatment, 
we investigated whether co-inhibition of EGFR and ROCK causes cell death. 
However, we did not find any indication of apoptosis such as floating cells, 
PARP or caspase 3 cleavage, or Annexin V and PI positivity in HCC1806 or 
MDA-MB-231 cells (data not shown). We therefore investigated whether either 
of the inhibitor treatments or the combination would affect how these tumor 
cells progress through the cell cycle. DNA replication, as revealed by BrdU 
incorporation during the S-phase, was mildly affected by the single treatments, 
whereas the combination of EGFR and ROCK inhibitors completely prevented 
MDA-MB-231 cells from progressing through this cell cycle phase (Fig. 5A). 
Upon single treatment, we observed a two-fold reduction in the number cells 
that incorporated BrdU (corresponding to S-phase cells) while combination 
treatment caused a four-fold reduction. 
 We next analyzed the individual cell cycle phases of single diploid. 
Consistent with the BrdU incorporation results of the general population, we 
observed a two-fold reduction in the number of cells that went through the 
S-phase upon EGFR or ROCK inhibitor treatment. Additionally, ROCK inhibitor 
alone and in combination with EGRF inhibition caused a two-fold increase 
in the number of cells in G2 phase as well as an increase in the number of 
polyploid cells (Figure 5B). Importantly, the number of diploid cells going 
through S-phase upon combination treatment was almost six times less than 
singe-drug-treated cells. 
 Consistently, phosphorylation of pRb, which is essential for the cells 
to progress from G1 to S phase, was not affected in cells treated with either 
inhibitor alone but was almost abolished upon combination treatment. The 
reduction in pRb phosphorylation was accompanied by loss of Cyclin A and 
Cdk2, as well as p27Kip1, which has an essential role in assembling Cyclin-
Cdk complexes [62] (Figure 5C). These data suggest that combined inhibition 
of EGFR and ROCK impedes cells from progressing through the cell cycle, 
arresting cells in both G1 and G2 phases of the cell cycle and consequently 
affecting the proliferative capacity of TNBC cells.
Ch
ap
te
r 2
53
Discussion
Targeted therapy has arisen as an alternative to cytotoxic drugs in cancer 
therapy, in some cases increasing the response rate of patients as well as 
overall survival and progression-free survival [36]. The major challenge of 
targeted therapy is the issue of drug resistance, which eventually develops. 
More durable clinical responses are seen when targeted therapies were 
combined with radiotherapy, chemotherapy or other targeted compounds 
[37, 38]. Here, we report combined EGFR-ROCK inhibition as a potential 
combination treatment for triple-negative breast cancer.
 We performed two loss-of-function screens in vivo and in vitro using 
two distinct TNBC cell lines in order to uncover common potential targets in 
TNBC. We ensured focusing on more clinically relevant targets by 1) using a 
library comprising shRNAs targeting kinases which are generally targetable 
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by drugs; and 2) comparing shRNA loss in tumors relative to cultured cells, 
corresponding to the two arms in the screen. Our hit list contains genes coding 
kinases with established oncogenic functions such as MET [39], EGFR [40, 
41], AKT, mTOR [42-44], RSK2 [45] as well as genes that do not (yet) have an 
established role in cancer progression (NEK5, SIK2). Our hit list also comprised 
genes like ROCK1 and FAK that are known to play a role in migration, invasion 
and metastasis but have only recently been implicated in tumor progression 
[46-49]. 
 It is increasingly clear that for durable clinical responses to occur one 
needs to develop effective combinatorial strategies [26, 50]. For this reason, we 
combined our in vivo screening with an in vitro pharmacologic approach in 
order to find more effective, combined treatment options. We combined eight 
compounds with each other in a matrix setting in which five doses of one drug 
were combined with five doses of a second drug. We used this experimental 
system to assess the effect on the proliferation of HCC1806 and MDA-MB-231 
cells. This resulted in the identification of two pairs of inhibitors that 
showed synergistic effects: EGFR + ROCK, and AKT + mTOR inhibitors. Since 
mTOR inhibition increases AKT activity by disrupting feedback inhibition 
[51,52], vertical targeting of the PI3K-AKT-mTOR pathway has proven to be a 
promising approach in several cancer types [31-33], with clinical trials ongoing 
[34]. We find this combination with two different inhibitors targeting mTOR 
(Everolimus and AZD8055), validating the accuracy of our system. 
 The anti-proliferative effect of the combination of a ROCK and EGFR 
inhibitor on the other hand, has not been described before. ROCK, an effector 
of the small GTPase Rho, is widely studied in the context of cell shape and 
movement. It is known to be a major regulator of migration, influencing 
cellular characteristics such as contraction, actin organization and polarity 
[53]. Consistent with this, we observed major morphological changes upon 
ROCK inhibition in all cell lines we analyzed. Aside from its critical role in 
migration, ROCK inhibition has been shown to cause defects in cytokinesis 
[54]. In line with this, we observed an increased number of G2 and polyploid 
cells upon treating with ROCK inhibitor. However, although this slowed down 
the proliferation rate, it did not severely impair cell growth in the long run. 
Also in vivo, ROCK inhibitor had no impact on tumor growth. 
 ROCK inhibition as an anti-tumor treatment is not widely investigated 
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but its potential use in combination with chemotherapy or other tyrosine 
kinase inhibitors is increasingly recognized [55]. For instance, ROCK and Brc-
Abl co-inhibition leads to apoptosis and cell cycle defects in chronic myeloid 
leukemia cells [56]. We also recently showed that in combination with either 
BRAF, ERK or MEK inhibition, ROCK inhibition delays melanoma growth [29, 
57]. In several TNBC cell lines, we observed substantial growth impairment 
in vitro upon treatment with both EGFR and ROCK inhibitors compared with 
single-agent treatment. A similar pattern was seen for in vivo growth of 
HCC1806 cells. However, unlike the recent findings for lung cancer [58], we 
did not find a correlation between the response of TNBC cells to combination 
treatment and EGFR mutation status, phospho-EGFR, phospho-MYPT or ROCK 
protein levels, suggesting a cell type-specific component. 
 To begin to explore the mechanistic basis for our observations, we found 
that co-inhibition of EGFR and ROCK induces cell cycle arrest in HCC1806 and 
MDA-MB-231 cells. This was accompanied by a decrease in the protein levels 
of cyclin A, Cdk2, p27 and phosphorylated pRB. Cyclin A – Cdk2 complex is 
active at two points in the cell cycle: during onset of S phase and in early G2 
phase. The function of Cyclin A – Cdk2 in G2 is thought to be the regulation of 
Cyclin B – Cdk1 levels to enter mitosis [59-61]. Therefore, absence of an active 
Cyclin A – Cdk2 complex would cause insufficient levels of Cyclin B – Cdk1 
complex formation, leading to a failure in mitosis entry and causing the cells to 
accumulate at G2 phase. Although p27 is known to act as a cell cycle inhibitor 
by inhibiting the activity of Cyclin E – Cdk2 complex, it also plays a critical 
role in the assembly of Cyclin D – Cdk4 complexes [62, 63], allowing cells to 
progress through the G1 phase. Another major inhibitor of the cell cycle is pRB. 
In its unphosphorylated form, pRB binds to E2F and inhibits its transcriptional 
activity whereas phosphorylated pRB dissociates from E2F, allowing cell cycle 
gene expression and entry into the S phase [64]. Co-inhibition of EGFR and 
ROCK in triple-negative breast cancer cells caused decrease in phosphorylated 
pRB, p27, Cyclin A and Cdk2 protein levels, correlating with an almost complete 
loss of the ability of the cells to replicate and consequently, proliferate.
 In conclusion, we demonstrate here that EGFR and ROCK are potential 
in vivo targets for triple-negative breast cancer in a combination setting: co-
inhibition of EGFR and ROCK has a profound impact on cell proliferation in a 
panel of TNBC cell lines, in vitro as well as in mice, which was at least partially 
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explained by the induction of cell cycle arrest. This proof of concept warrants 
further validation and optimization to determine whether this ought to be 
studied in the clinic. 
Materials and Methods
Cell Culture and Reagents
Hek279T, MDA-MB-231, LM2, BT549, Cal51, Cal120 cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 9% fetal 
bovine serum (Sigma), 2 mM glutamine, 0.1 mg/ml penicillin and 0.1 ml/ml 
streptomycin (Gibco). HCC1806, HCC38, Hs578T cells were maintained in RPMI 
supplemented with glutamine.
Hek293T cells were used for lentivirus production as described previously 
[23]. shRNAs targeting EGFR and ROCK were obtained from the TRCs1.0 library 
and were as follows: shEGFR-1: TRCN0000121068, shEGFR-2: TRCN0000010329, 
shEGFR-3: TRCN0000121206, shEGFR-4: TRCN0000121203, shROCK1-1: 
TRCN0000002163, shROCK1-2: TRCN0000121316, shROCK1-3: TRCN0000121095, 
shROCK1-4: TRCN0000002161 (TRC Library, Sigma).
For long-term cell growth assays, cells were seeded on 6-well or 12-well plates 
(Corning). Drugs were added on the following day and media was refreshed 
every third day with new compound dilutions. At the end time point, the cells 
were stained with crystal violet. ROCK inhibitors used were GSK269962A 
(Axon) and Fasudil (Selleck). EGFR inhibitors used were Gefitinib (MedChem) 
and Afatinib (Selleck).
For DNA content and cell cycle analysis, sub-confluent cells were incubated 
with 10uM Bromdeoxyuridine (BrdU) for 1.5 hours, trypsinized, fixed in 70% 
ice-cold ethanol, and stained with anti-BrdU and Propidium Iodide (PI).
In vivo and in vitro screens
A lentivirus-based Kinome shRNA library targeting ~500 kinases and kinase-
related genes with ~3000 shRNAs was assembled from the human genome-
wide shRNA collection (TRCHs1.0). The screens were set up and performed as 
described before [22]. Briefly, 1.5x106 cells were seeded in 10 cm culture dishes 
and infected for 6 hours (MOI<0.2) with lentivirus-containing supernatant. 
After 3 days of puromycin selection (1 mg/ml), the reference samples were 
collected. The remaining cells were either mixed with 1:1 matrigel and injected 
into the 4th mammary fat pad of 6 female NOD/SCID IL2γnull (NSG) mice 
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(0.5x106 cells/mouse), or seeded on 6x10cm dishes and maintained in culture 
in parallel (0.5x106 cells/dish). The cells and the tumors were harvested after 
two and three weeks, respectively. This procedure was repeated for each of the 
4 Kinome library pools. For the quantification of shRNAs in all samples, gDNA 
was isolated (DNeasy Blood and Tissue kit, Qiagen) and shRNAs were quantified 
after PCR amplification and deep sequencing (Illumina HiSeq2000). Results 
were analyzed with the DESeq package of R/Bioconductor [24, 25]. shRNAs that 
are detected with less than 200 reads on average in the references and in in 
vitro samples were excluded from the analysis. Normalized read numbers were 
compared between tumors and cultured cells in order to determine the shRNAs 
that were lost 30% more in vivo than in vitro. Genes targeted with at least two 
shRNAs with a false discovery rate < 0.1 were considered hits, provided that 
they were not enhanced more than 20% in in vitro samples compared with the 
reference samples.
Synergy Matrix
HCC1806 and MDA-MB-231 cells were seeded onto 384-well plates at 103 and 
2.5*103 cells/well, respectively, and treated with 5 serial dilutions of one drug 
combined with 5 serial dilutions of a second drug in a matrix format. The 
maximum dose used per drug did not exceed its IC50. In order to obtain a dose-
response curve from the drugs in the matrices, cells were treated with six more 
serial dilutions of higher doses of each drug outside of the matrix. After 72 
hours, cells were incubated for two hours in CellTiter Blue at 1:20 dilution and 
the absorbance was measured at TECAN. Synergy matrix calculations were 
done as described before [26].
Immunoblot analysis and antibodies
Cells were harvested in ice by scraping in ice cold 1X PBS and the pellets 
were lysed in RIPA buffer (50 mM TRIS pH 8.0, 150 mM NaCl, 1% Nonidet P40, 
0.5% sodium deoxycholate, 0.1% SDS, complete protease inhibitor cocktail 
(Roche), and phosphatase inhibitors 10 mM NaF, 1 mM Na3VO4, 1 mM 
sodium pyrophosphate, 10 mM beta-glycerophosphate). After sonication 
and centrifugation the protein concentrations were determined using the 
Bio-Rad protein assay (Bio-Rad). Samples were loaded on 4-12% Bis-Tris 
polyacrylamide-SDS gels (NuPAGE) and transferred on to nitrocellulose 
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membranes (Amersham). Membranes were blocked in 4% skimmed milk 
powder dissolved in 0.2% Tween-containing 1X PBS and incubated with primary 
antibodies followed by secondary antibodies (Invitrogen). Primary antibodies 
used were EGFR (sc-03, Santa Cruz), EGFRY2068 (ab5644, Abcam), ROCK1 
(611137, BD), MYPTThr696 (ABS45, Millipore), ERKThr202/Tyr204 (4370S, Cell 
Signaling), ERK (9102, Cell Signaling), Hsp90 (sc-7947, Santa Cruz), p27 (610241, 
BD), pRBSer807/811 (9308S, Cell Signaling), CDK2 (sc-163, Santa Cruz), Cyclin A 
(sc-596, Santa Cruz).
 
In vivo experiments
All animal work was done in accordance with a protocol approved by the 
Netherlands Cancer Institute Animal Experiment Ethics Committee. Female 
NSG mice aged 5-8 weeks were used for all in vivo experiments. Human breast 
cancer cells were prepared as 107 cells/ml suspension in medium, mixed 1:1 
with growth factor reduced matrigel and 100ul of the mixture was injected into 
the 4th mammary fat pad of the mice on both sides (0.5*106 cells/injection). 
Mice were orally treated with drugs 6 days/week, starting one day after tumor 
inoculation. GSK269962 was dissolved in DMSO at 100mM and diluted in 10% 
Tween80 and 6.5% ethanol mix to 10mg/kg. Gefitinib was dissolved in DMSO 
at 200mM and diluted in 2% Tween80 to 90 mg/kg. Tumors were manually 
measured twice a week with a caliper and tumor volume was calculated by the 
formula a*b2/2 where ‘a’ is the longest diameter and ‘b’ is the perpendicular 
diameter to ‘a’. One-Way ANOVA corrected for multiple comparisons (Holm-
Sidak) was used to compare more than two experimental groups (Prism; 
GraphPad Software). Error bars represent standard error of the mean (SEM).
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Supplementary Figure 1. A. The complexity of the library was retained in all groups in the MDA-
MB-231 screen. Bars show the average number of shRNAs per biological group. Of the 3124 shRNAs 
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plates at 0.3*105 cells/well. Cells were stained with crystal violet after six days. Corresponding 
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Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer 
with very limited treatment options. We have previously shown that combined 
inhibition of EGFR and ROCK1 results in cell cycle arrest and death in TNBC cell 
lines. Here we demonstrate that this combination treatment causes autophagy, 
which is accompanied by rpS6 inhibition, leading to the demise of a subset of 
TNBC cells. Our data also suggest that Rab11 is a potential biomarker that can 
be used to predict response to EGFRi+ROCKi treatment
Introduction
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. 
It takes its name from the fact that these tumors lack the three receptors: 
estrogen (ER), progesterone (PR), and HER2 [1]. Although it is possible to cure 
TNBC by surgery and systemic therapy, treatment-resistant recurrences 
are common [2]. Despite extensive research, due to the absence of hormone 
receptors and the absence of a common genetic vulnerability, there has 
been no established targeted inhibitor treatment against TNBC yet [3]. Triple 
negative (TN) tumors can be sub-classified in several groups highlighting 
the heterogeneity of this group [4]. We previously carried out in vivo and in 
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vitro genetic screens complemented with pharmacologic screens in order 
to identify drug combinations that effectively impair TNBC cell growth. We 
reported that combined inhibition of EGFR and ROCK induces cell cycle arrest 
in TNBC cells [5]. 
 Cell cycle progression is a tightly controlled process with several 
checkpoints to ensure correct DNA replication. Cell cycle arrest is therefore a 
protective mechanism against DNA damage. By temporarily halting the cycle, 
cells give the DNA repair machinery time to repair mismatches [6]. However, 
prolonged cell cycle arrest (for example induced by drugs) can eventually lead 
to cell death [7, 8]. 
 There are several mechanisms of cell death including apoptosis, 
necroptosis, or autophagy [9]. Autophagy is a caspase-independent process, 
which involves digestion of retired organelles in order to maintain metabolic 
homeostasis. Although autophagy is a protective mechanism that allows 
cells to survive certain stresses such as starvation, it can also lead to cell 
death [10]. Autophagy involves formation of vesicles that engulf and degrade 
cytoplasmic components and therefore employs vesicle trafficking and 
recycling machineries of the cell. 
 Here we demonstrate that the combination treatment of EGFR 
inhibitor (EGFRi) and ROCK inhibitor (ROCKi) induces autophagy and inhibits 
rpS6. We also show that the subset of TNBC cell line that are sensitive to the 
combination treatment express lower levels of Rab11, a small GTPase involved 
in the localization of recycling endosomes. 
Results
EGFRi+ROCKi treatment causes a major change in cell-death-related 
protein abundance
As we have shown earlier, combined inhibition of EGFR and ROCK induces cell 
cycle arrest in triple-negative breast cancer cell lines [5]. However, we did not 
detect a differential change in common apoptotic markers upon combination 
treatment. We therefore compared the protein expression profiles of two TNBC 
cell lines treated with EGFRi, ROCKi, or combination by mass spectrometry. 
Clustering and principal component analyses show that the technical 
replicates of each treatment cluster together, with the exception of one 
EGFRi-treated replicate of Cal51 cells, which was excluded from the analysis. 
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Furthermore, DMSO- and EGFRi-treated cells have almost indistinguishable 
profiles, allowing us to compare ROCKi- and combination-treated samples 
directly with EGFRi-treated ones (Figure 1). Our analysis revealed 62 proteins 
differentially regulated upon combination treatment compared to EGFRi 
and ROCKi treatments alone (Table 1). Consistent with our previous findings, 
several of these proteins are involved in various cell death processes (Table 2). 
EGFRi+ROCKi treatment induces autophagy in TNBC cells
One of the responses of cells to stress is autophagy induction [11]. Among the 
differentially regulated proteins upon combination treatment, there are three 
upregulated proteins that are crucial for autophagy induction: ATG5, SQSTM1 
and MAP1S [12-14] (Table1). We therefore investigated whether the autophagy 
pathway plays a role in the cells’ response to combination treatment. As has 
been reported previously [15, 16], EGFRi treatment caused an increase in LC3 
and p62 protein levels in MDA-MB-231 cells (Figure 2A), which indicates 
autophagy activation. ROCKi treatment alone did not have any influence 
on autophagy, while the levels of LC3 and p62 in combination-treated cells 
remained high. Moreover, combined inhibition of EGFR and ROCK led to 
increased AMPK phosphorylation, which is another indication of autophagy 
induction [17, 18] (Figure 2A). Interestingly, in MDA-MB-231 cells, we observed 
a steep decrease in phosphorylated rpS6 levels upon ROCK inhibition. rpS6 
phosphorylation declined even further in case of combined EGFRi+ROCKi 
treatment. The drug-induced changes in LC3 and rpS6 phosphorylation were 
reproducible in HCC1806, Cal120 and Hs578T cells (Figure 2B).
Rab11 is a potential biomarker for EGFRi+ROCKi treatment response
EGFRi+ROCKi combination treatment is effective, but this is observed only for 
a subset of TNBC cell lines. In order to identify a marker that would predict 
response to this treatment, we compared the expression profiles of cells 
that respond to combination treatment to those which do not. We found 
that responsive cell lines generally express lower levels of Rab11 than non-
responsive cell lines (Figure 3). This result suggests that Rab11 can be used 
as a biomarker that distinguishes TNBC patients who would respond to this 
regimen from those who will not.
74
Chapter 3
D
M
SO
EG
FR
i
EG
FR
i +
 
R
O
CK
i
R
O
CK
i
DMSO EGFRi ROCKiEGFRi + 
ROCKi
1.00
0.98
0.96
0.94
0.92
0.90
0.88
0.86
-100 -80 -60 -40 -20 0 20 40 60
Principal Component 1
60
40
20
0
-20
-40
-60
-80
-100
Pr
in
ci
pa
l C
om
po
ne
nt
 2
A.
B.
D
M
SO
EG
FR
i
EG
FR
i +
 
R
O
C
K
i
R
O
C
K
i
DMSO EGFRi ROCKiEGFRi + 
ROCKi
1.00
0.98
0.96
0.94
0.92
0.90
0.88
0.86
-80 -60 -40 -20 0 20 40 60 80
60
40
20
0
-20
-40
-60
80
Principal Component 1
Pr
in
ci
pa
l C
om
po
ne
nt
 2
DMSO
EGFRi
ROCKi
EGFRi + ROCKi
DMSO
EGFRi
ROCKi
EGFRi + ROCKi
Figure 1. EGFRi, ROCKi and EGFRi+ROCKi treated replicates cluster with eachother.  Clustering and 
principal component analysis of mass spectrometry data from A. Cal51 B. HsT578 cells.
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Gene Symbol Cal51 Hs578T Gene Symbol Cal51 Hs578T
AARS 0.7228 0.451105 MVB12A -0.604424 0.096154
ACO1 0.160127 0.469481 NAMPT 0.174912 0.795114
AHDC1 -0.677768 -0.98817 NOP16 -0.915475 -0.599867
APLP2 1.959162 3.232527 NRP1 0.835961 0.958799
APOB 2.82486 2.571492 NUP50 -0.289565 -0.219902
APP 1.38132 1.620807 PEPD 0.31822 0.553846
ATG5 0.680475 0.598467 PGM3 0.173882 0.421038
ATP6V1H 0.595647 1.064075 PHF3 -0.674379 -0.867216
BLMH 0.12071 0.646992 PLD3 0.352009 1.378988
CAPRIN1 -0.560199 -1.112468 POLD3 -0.594036 -1.785166
CBR1 0.46472 0.251702 POLE3 -0.725363 -1.600233
CCPG1 1.888774 3.279419 RAB30 0.529245 -0.715224
CD3EAP -0.418634 -0.458585 ROMO1 -0.786354 -1.192555
CNN1 -0.768212 -0.825077 SART1 -0.58532 -1.037988
COX17 -0.656102 -1.333068 SCAF11 -0.330623 -1.410321
CSRP2 0.070032 -1.0758 SDCBP 1.028982 3.683934
DGKA 0.398165 0.657204 SERINC1 1.271557 2.531571
EFHD1 -0.299403 -0.87754 SMARCA1 -0.32816 -1.092385
ENOPH1 0.436665 0.758141 SQLE 1.897875 2.02255
GALE 0.44481 0.334022 SQSTM1 1.20899 4.098365
GPX1 0.103865 0.472358 SS18 -0.358664 -0.911424
HMGN1 -0.646607 -1.448202 SURF6 -0.39139 -0.815758
HMOX1 2.284882 2.174007 TMEM59 2.441147 3.604981
IFNGR1 2.633912 3.013862 TNFRSF21 1.514087 2.054032
INPP5A -1.663326 -1.266991 TPRG1L 0.76399 2.227964
ITGA3 0.820895 0.63918 VCAN -0.539701 -1.004042
ITM2B 1.571899 2.922669 VPS26A 0.484959 0.185742
LRP10 1.363656 2.472543 WIZ -0.416215 -1.49781
MAP1S 0.399535 0.365696 ZEB1 -0.410516 -0.984669
MEAF6 -0.730823 -0.661398 ZNF148 -0.671072 -0.984205
MMP14 0.685141 1.375302 ZNF217 -0.876905 -1.208413
Combi / ROCKi Combi / ROCKi
Table 1. Differentially expressed proteins upon EGFRi+ROCKi treatment. The list of differentially 
expressed proteins upon EGFRi+ROCKi treatment was obtained by extracting the non-overlapping 
proteins between samples treated with EGFRi and ROCKi, and EGFRi and EGFRi+ROCKi. These 
two lists were then compared again for non-overlapping proteins. Proteins that were commonly 
differentially expressed in Cal51 and Hs578T cells are listed here.
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Figure 2. EGFRi+ROCKi treatment induces autophagy in TNBC cells. A. Western blots showing the 
changes in autophagy markers and rpS6 phosphorylation in MDA-MB-231 cells. Hsp90 is used as 
loading control. B. Western blots showing the changes in LC3 and rpS6 phosphorylation in HCC1806, 
Hs578T and Cal120 cells. Actin is used as loading control.
Discussion
Recurrent TNBC is a hard-to-cure cancer type owing to lack of (targeted) 
therapy options. We previously performed two in vivo screens paired with 
an in vitro inhibitor combination screen to identify novel therapeutic targets 
in TNBC cells. These screens revealed EGFR+ROCK inhibitor combination as 
synergistically lethal. We reported that this combination causes cell cycle 
arrest in TNBC cells [5]. This study complements our previous findings by 
showing that growth impairment caused by combination treatment is a result 
of autophagy activation combined with rpS6 inhibition. 
 Autophagy is a self-digesting mechanism of the cells whereby old 
organelles are disposed of. It is also one of the several response mechanism 
cells use upon facing stress conditions. In the context of cancer, autophagy 
can have both oncogenic and tumor suppressive functions [19]. Autophagy 
induction can protect cancer cells, for example by maintaining metabolic 
homeostasis in low nutrient availability. Moreover, it has been shown to induce 
a drug-resistant phenotype upon anti-cancer treatment [20, 21]. On the other 
hand, autophagy is also known to ensure normal growth and induce cell death 
to avoid abnormal proliferation [22]. Paradoxically, autophagy can also lead to 
treatment sensitivity in cancer cells [23]. In our mass spectrometry analysis, 
we found three differentially upregulated autophagy-promoting genes in 
cells treated with EGFRi+ROCKi: ATG5, SQSTM1, MAP1S. Independent from its 
essential role in autophagy, ATG5 has also been shown to have a pro-apoptotic 
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role [24]. EGFR is a known regulator of autophagy since its inhibition blocks 
signaling via mTOR, which is a direct inhibitor of autophagy [25]. Consistent 
with earlier reports [15, 16], our data indicate that EGFR inhibition activates 
autophagy as evidenced by an increase in LC3-II and p62 protein levels. 
This activation is maintained when the cells are treated with EGFRi+ROCKi 
combination, likely only due to EGFRi as ROCKi alone had no effect on either 
of the two molecules. Additionally, AMPK phosphorylation, which is another 
indication of autophagy [17, 18], increased only upon combination treatment. 
Interestingly, as opposed to other cancer types such as lung cancer [26], we 
did not observe an increase in phosphorylated AMPK when TNBC cells 
were treated with EGFRi alone. It is more likely that autophagy induction by 
EGFRi has a protective role in our system since we observe minimal growth 
impairment in TNBC cells upon EGFRi treatment.
 On the other hand, ROCK inhibition alone caused a severe reduction in 
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Figure 3. Rab11 is a potential biomarker for EGFRi+ROCKi treatment response. Protein expression 
profiles were compared of the cell lines that respond (MDA-MB-231, HCC1806, Cal51, Cal120, Hs578T, 
HCC38, BT549) and that do not respond (Cal148, HCC1187, MDA-MB-157, MFM223, BT20, HCC1395, 
HCC1937, MDA-MB-436, MDA-MB-468) to the combination treatment.
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rpS6 phosphorylation, which was further reduced to undetectable levels when 
the cells were treated with EGFRi+ROCKi combination. rpS6 is a downstream 
target of PI3K-AKT-mTOR-p70S6 pathway that is commonly involved in cancer 
development. Several cancer types have been shown to be associated with 
the components of this pathway [27-30]. High p-prS6 levels are significantly 
correlated with aggressive disease and downregulation of rpS6 causes cell 
cycle arrest in NSCLC [31]. Dephosphorylation of rpS6 would indicate that 
mTOR is inactive, which would release the block on autophagy. Although 
we did not observe any detectable changes in autophagy markers in ROCKi 
treated cells, LC3-II levels are generally higher in the combination treated cells 
compared to EGFRi treated cells, suggesting an additive effect.
 Autophagy is a process with multiple steps: autophagy-related-genes 
(ATGs) form phagophores, these develop into autophagosomes that contain 
portions of cytoplasm, which then mature into autolysosomes by merging with 
lysosomes [25]. Autophagosome formation involves endocytosis and therefore 
the molecules that play a role in vesicle trafficking. Rab11 is a small GTPase 
that regulates vesicle trafficking of recycling endosomes as well as exocytosis 
of recycling vesicles [32,33]. It has recently been shown that Rab11 contributes 
to autophagosome formation, promoting autophagy [34]. Interestingly, our 
differential gene expression analysis showed that TNBC cell lines that are 
sensitive to EGFRi+ROCKi treatment have lower levels of Rab11 compared 
to that of TNBC cell lines that do not respond to combination treatment. It 
therefore is possible that despite the LC3-II accumulation, autophagy process 
cannot proceed due to lack of Rab11. Combined with rpS6 inhibition, blockage 
of autophagy consequently causes the demise of the cells. This data also 
indicates that Rab11 can be a potential biomarker to predict response to EGFRi-
ROCKi combination treatment in TNBC.
Materials and Methods
Cell Culture and Reagents
MDA-MB-231 and Cal120 cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 9% fetal bovine serum (Sigma), 2mM 
glutamine, 0.1mg/ml penicillin and 0.1ml/ml streptomycin (Gibco). HCC1806 
and Hs578T cells were maintained in RPMI supplemented with glutamine.
For drug treatment experiments, drugs were added on the following day of 
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seeding. ROCK inhibitor used was GSK269962A (ROCKi) (Axon) and EGFR 
inhibitor was Gefitinib (EGFRi) (MedChem). MDA-MB-231, HCC1806, Cal120 
and Hs578T cells were treated with 20μM EGFRi. ROCKi concentration for 
MDA-MB-231 was 4.8μM, for HCC1806 was 2.4μM, for Cal120 was 30μM, for 
Hs578T was 1.2μM. 
Immunoblot analysis and antibodies
Cells were harvested in ice by scraping in ice cold 1X PBS and the pellets 
were lysed in RIPA buffer (50 mM TRIS pH 8.0, 150 mM NaCl, 1% Nonidet P40, 
0.5% sodium deoxycholate, 0.1% SDS, complete protease inhibitor cocktail 
(Roche), and phosphatase inhibitors 10 mM NaF, 1 mM Na3VO4, 1 mM 
sodium pyrophosphate, 10 mM beta-glycerophosphate). After sonication and 
centrifugation the protein concentrations were determined using the Bio-Rad 
protein assay (Bio-Rad). Samples were loaded on 4-12% Bis-Tris polyacrylamide-
SDS gels (NuPAGE) and transferred on to nitrocellulose membranes 
(Amersham). Membranes were blocked in 4% skimmed milk powder dissolved 
in 0,2% Tween-containing 1X PBS and incubated with primary antibodies 
followed by secondary antibodies (Invitrogen). Primary antibodies used were 
LC3 (5F10, Nanotools), p62 (610832, BD Biosciences), AMPKThr172 (40H9, Cell 
Signaling), rpS6 (5G10, Cell Signaling), rpS6Ser235/236 (Cell Signaling), Hsp90 
(sc-7947, Santa Cruz), Actin (AC-74, Sigma).
Mass spectrometry analysis
Cal51 and Hs578T cells were harvested in triplicates in cold PBS after a 2-day 
treatment with DMSO, EGFRi, ROCKi or combination. The cellular pellets were 
resuspended in lysis buffer containing 1% (w/v) sodium deoxycholate (SDC), 10 
mM TCEP, 40 mM chloroacetamide, 100 mM Tris, pH 8.5, supplemented with 1 
tablet of Complete mini EDTA-free mixture (Roche) and 1 tablet of PhosSTOP 
phosphatase inhibitor cocktail mixture (Roche) per 10ml of lysis buffer, and 
subsequently lysed by boiling for 5 min at 95°C and sonication (Bioruptor, 
model ACD-200, Diagenode) for 15 min at level 5 (30 sec ON, 30 sec OFF). Cell 
debris was then removed by centrifugation at 20.000 × g for 15min at 4°C. The 
supernatant containing the clarified lysate was transferred to a new vial and 
protein concentration was determined using the Bradford assay (Biorad). The 
lysate was diluted 1:10 with 50 mM ammonium bicarbonate for Lys-C-trypsin 
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digestion. Protein digestion was performed overnight at 37°C with Lys-C 
(Wako) at an enzyme/protein ratio 1:75 and trypsin (Sigma) at an enzyme/
protein ration of 1/50. The digest was acidified by adding 4% formic acid (FA) 
to precipitate SDC and samples were subsequently desalted using Sep-Pak C18 
cartridges, dried in a vacuum centrifuge and stored at -80°C for further use. 
 For high pH reversed-phase (HpH) peptide fractionation, 50 μg of the 
desalted digest was reconstituted in 10mM ammonium hydroxide, pH 10 and 
loaded on a Phenomenex Gemini C18 3 µm 100 x 1.0 mm column using an 
Agilent 1100 binary pump. The peptides where concentrated on the column 
at 100 µl/min using 100% buffer A (10mM Ammonium Hydroxide, pH 10) for 2 
minutes after which the fractionation gradient initiated as follow: 5% solvent B 
(10mM ammonium Hydroxide in 90% ACN, pH 10) to 30% B in 53 minutes, 70% B 
in 7 minutes and increased to 100% B in 3 minutes at a flow rate of 100 µl/min. 
In total 60 fractions of 1 minute were collected using an Agilent 1260 infinity 
fraction collector, and were pooled into 5 fractions using the concatenation 
strategy as described [35]. The pooled fractions were dried in a vacuum 
centrifuge and stored at -80°C for further use.
 All LC-MS/MS data were acquired on an Orbitrap Q Exactive Plus Mass 
Spectrometer (Thermo Fisher) coupled to an Agilent 1290 Infinity UHPLC 
(Ultra-High Pressure Liquid Chromatography) system (Agilent Technologies). 
Both the trap (Dr Maisch Reprosil C18, 3 μm, 2 cm x 100 μm) and the analytical 
(Agilent Poroshell EC-C18, 2.7 μm, 50 cm x 75 μm) columns were packed in-
house. Peptides were trapped for 10 min at 5 μl/min in 100% solvent A (0.1 M 
acetic acid in water). Separation was performed at a column flow rate of ~300 
nl/min (split flow from 0.2 ml/min) and the gradient was as follows: 13% up 
to 40% solvent B (0.1 M acetic acid in 80% acetonitrile) in 95 min, 40-100% in 
3 min and finally 100% for 1 min. The mass spectrometer was programmed 
in the data-dependent acquisition mode. Full scan MS spectra from m/z 
375-1,600 were acquired at a resolution of 35.000 with an automatic gain control 
(AGC) target value of 3e6. The 10 most intense precursor ions were selected for 
fragmentation using HCD. MS/MS spectra were obtained at a 17,500 resolution 
with an AGC target of 5e4. HCD fragmentation was performed at a normalized 
collision energy (NCE) of 25%.
 Raw files were processed with MaxQuant (version 1.5.3.28) [36]. The 
Andromeda search engine [37] was used to search the MS/MS data against 
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the human Uniprot database (20.193 entries, version November 2015). 
Trypsin/P was the chosen enzyme allowing up to two missed cleavages. 
Carbamidomethylation (C) was set as a fixed modification, while oxidation 
(M) and acetyl (Protein N-term) were set as variable modifications. Peptide 
spectrum match (PSM) and protein identifications were filtered using a target-
decoy approach at false discovery rate (FDR) of 1%. Label free quantification 
(LFQ) was done using the MaxLFQ algorithm [38] with the following parameters: 
LFQ minimum ratio count was set to 2, the Fast LFQ option was enabled, LFQ 
minimum number of neighbors was set to 3, and the LFQ average number of 
neighbors to 6. The “match between runs” feature was enabled with a match 
time window of 0.7 min and an alignment time window of 20 min.
 The quantified proteins were processed and analyzed using the 
PaDuA package (manuscript in preparation). The data were filtered to remove 
reverse, only identified by site and potential contaminant proteins. Resulting 
protein quantities were log2 transformed prior to statistical analysis. Inter-
sample correlation was used to check reproducibility across replicates in 
each condition. One identified outlier (EGFRi-treated Cal51 replicate 2) was 
excluded prior to further analysis. Principal Component Analysis (PCA) was 
used to assess agreement within and separation between sample groups. 
Significantly upregulated proteins were used to perform Gene Ontology (GO) 
enrichment using the DAVID web service.
Reverse phase protein array
Fifteen triple negative cell lines were classified into cell lines which were 
sensitive (BT549, CAL120, CAL51, HCC1806, HCC38, HS578T and MM231) or 
resistant (BT20, CAL148, HCC1187, HCC1395, HCC1937, MFM223, MM157, MM468) 
to the combination treatment in a colony formation assay. Reverse-phase 
protein array (RPPA) data was available for these 15 cell lines (Jastrzebski et al., 
unpublished data), providing measurements of 152 total and phosphorylation 
epitope levels. The RPPA signals were log transformed and median centered, 
and compared between the groups of sensitive and resistant cell lines with 
two-sided t-tests. P-values were adjusted for multiple testing using false 
discovery rate correction. Total Rab11 levels showed differential expression 
with q=0.05
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Abstract
Fra-1 (Fos-related antigen-1) is a member of the AP-1 (activator protein-1) 
family of transcription factors. We previously showed that Fra-1 is necessary 
for breast cancer cells to metastasize in vivo, and that a classifier comprising 
genes that are expressed in a Fra-1-dependent fashion can predict breast 
cancer outcome. Here, we show that Fra-1 plays an important role also in colon 
cancer progression. Whereas Fra-1 depletion does not affect 2D proliferation 
of human colon cancer cells, it impairs growth in soft agar and in suspension. 
Consistently, subcutaneous tumors formed by Fra-1-depleted colon cancer cells 
are three times smaller than those produced by control cells. Most remarkably, 
when injected intravenously, Fra-1 depletion causes a 200-fold reduction in 
tumor burden. Moreover, a Fra-1 classifier generated by comparing RNA profiles 
of parental and Fra-1-depleted colon cancer cells can predict the prognosis 
of colon cancer patients. Functional pathway analysis revealed Wnt as one 
of the central pathways in the classifier, suggesting a possible mechanism of 
Fra-1 function in colon cancer metastasis. Our results demonstrate that 
Fra-1 is an important determinant of the metastatic potential of human colon 
cancer cells, and that the Fra-1 classifier can be used as a prognostic predictor 
in colon cancer patients. 
Introduction
Metastasis is the main reason for many solid tumors to be life-threatening. The 
metastatic cascade involves several steps, ranging from dissemination from 
the primary tumor to growth at a secondary site. The acquisition of metastatic 
capability by tumor cells can be associated with Epithelial-Mesenchymal 
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Transition (EMT). Upon EMT, tumor cells are able to invade through the 
basement membrane of the primary tissue and stroma, and to enter the blood 
circulation. They often become anoikis resistant, which allows them to survive 
in the absence of attachment. Finally, they associate with the endothelium and 
extravasate to a secondary tissue. For outgrowth at secondary sites, the newly 
formed tumor foci need to induce angiogenesis [1, 2]. Metastases are often 
difficult to cure because they can be widespread, affecting tissue function, and 
they are usually resistant to conventional therapies. Furthermore, intervention 
of metastatic cancer progression is rarely efficient due to lack of early detection 
methods. Therefore, it is crucial to predict metastatic potential of disease and 
to target metastasis. 
 One of the well-known regulators of metastasis is the Activator Protein 
1 (AP-1) complex. AP-1 is a family of transcription factors regulating a broad 
spectrum of cellular processes including proliferation, migration and invasion 
[3]. AP-1 dimers are formed by Fos (c-FOS, FOSB, Fra-1, Fra-2), Jun (c-JUN, 
JUNB, JUND), ATF and MAF protein families. AP-1 members are encoded by 
immediate early genes that are rapidly activated and deactivated in response 
to a wide range of stimuli. Although some AP-1 components have been 
reported to act as tumor suppressors, AP-1 complexes are mostly known for 
their ability to induce oncogenic transformation among other processes such 
as proliferation, apoptosis, invasion and angiogenesis [4]. c-Fos, c-Jun and 
Fra-1 are among the AP-1 components whose overexpression correlate with 
poor prognosis in several types of malignancies including ovarian, lung, and 
breast cancers [5-7]. 
 AP-1 is regulated by the Ras/Raf/MEK/ERK [8], [9] and the Wnt [10] 
pathways. The Wnt pathway is often deregulated in colon cancer as a result 
of activating mutations in beta-catenin (CTNNB1) or inactivating mutations 
in adenomatous polyposis coli (APC), which is a negative regulator of beta-
catenin. Wnt signaling is not only critical for developmental and oncogenic 
characteristics like proliferation, survival, and differentiation but also drives 
metastasis-related processes such as migration and cell polarity [11]. Previous 
reports have shown that the Wnt pathway negatively regulates Fos and FosB 
expression, whereas it increases Fra-1 mRNA levels in mouse epithelial cells 
[12]. Moreover, non-canonical Wnt signaling activates AP-1 through TCF 
binding to c-Jun in human colon cancer cells [13]. 
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 Fra-1 is one of the AP-1 transcription factors; it lacks a transactivation 
domain and has therefore a weak transforming activity. It forms heterodimers 
with Jun family members in order to activate target gene transcription. We and 
others have shown that Fra-1 promotes metastasis through various molecules: 
ADORA2B [7] in breast cancer, MMPs in breast cancer [14] and in lung epithelial 
cells [15], CD44 in mesothelioma [16], AXL in bladder cancer [17], FAK and EZH2 
in colon cancer [18, 19]. 
 Colorectal cancer (CRC) is among the most common cancers and 
one of the leading causes of cancer-related deaths worldwide. Traditional 
classification divides CRC into four main stages based on the local extent of the 
tumor, with three subtypes of stage III tumors based on the number of cancer-
positive nodes [20].  However, CRC is more heterogeneous than the categories 
used in the clinic with regard to progression, recurrence, metastasis and 
therapy response [21]. In the present study, we investigated the role of Fra-1 in 
colon cancer progression in vivo and the clinical impact of Fra-1 on disease 
outcome.
Results
Fra-1 is not critically required for proliferation of colon cancer cells in 
vitro 
As we have previously shown that Fra-1 is largely dispensable for human 
breast cancer cell growth in vitro but crucial for their ability to metastasize in 
vivo [7], we decided to investigate whether Fra-1 has a similar role in human 
colon cancer. Fra-1 was stably depleted in HT29, HCT116 and DLD-1 cells by 
two independent shRNAs (Figure 1A). There was no difference in proliferation 
rates of Fra-1-depleted cells and control cells on 2D culture plates (Figure 
1B). However, we found a 30-50% decrease in the number of cells surviving 
under anoikis-inducing conditions (Figure 1C) and a three-fold decrease 
in the number of colonies formed by Fra-1 deficient HT29 cells in soft agar 
(Figure 1D). Colo205 cells, which have low endogenous Fra-1 expression levels, 
successfully formed colonies in soft agar and survived in anoikis-inducing 
conditions; Fra-1 overexpression caused a mild but significant increase in the 
number cells in both cases (Suppl. Fig. 1A-C). Thus, Fra-1 is neither critically 
required for 2D nor 3D proliferation in vitro.
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Fra-1 is largely dispensable for primary colon tumor growth in vivo
In order to assess the role of Fra-1 in in vivo tumor growth, we next injected 
control and Fra-1-depleted HT29 cells subcutaneously into severely immune-
compromised (NOD/SCID IL2gamma, NSG) mice. Fra-1-depleted tumors 
grew approximately two-fold slower than control tumors (Figure 2A-B). 
Immunohistochemistry staining and western blots showed that Fra-1 levels 
were still low in these tumors at the end of the experiment (Figure 2C-D), 
indicating that there is no selective pressure to lose Fra-1 shRNAs during tumor 
progression. These data show that although Fra-1 contributes somewhat to the 
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Figure 1. Fra-1 is not critically required for proliferation of colon cancer cells in vitro. A. Fra-1 
depletion upon lentiviral transduction of two independent shRNAs. B. HT29 and HCT116 cells with 
or without Fra-1 knockdown were seeded into 6-well plates (30000 cells/well). The plates were 
stained with crystal violet after 7 days. C. HT29 cells with or without Fra-1 knockdown were seeded 
in duplicates in 0,3% agar suspension on top of a 1% agar base in 6-well plates at 24000 cells/well. 
After three weeks, colonies were stained with crystal violet and counted by Image J software (n=3). 
D. 0.4*106 cells were seeded into 6-well ultra-low-attachment plates in duplicate. The cells were 
harvested at day 6, trypsinized, resuspended and counted. Results presented are the combination 
of three experiments. 
Error bars represent SEM. Statistics: One-Way ANOVA. * p<0.05, ** p<0.01, *** p<0.001.
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expansion of colon cancer tumors in vivo, it is not strictly required.
Fra-1 is crucial for efficient metastatic spread of colon cancer cells
We and others have implicated Fra-1 as an important determinant of the 
metastatic capacity of cancer cells, which is associated with its ability to 
induce EMT and with clinical outcome [7, 22]. In order to determine the role 
of Fra-1 in colon cancer metastasis in vivo, we injected Fra-1-depleted HT29 
cells intravenously into NSG mice and monitored tumor expansion in time via 
a luciferase-dependent non-invasive in vivo imaging system. Whereas mice 
injected with cells carrying a control construct showed a substantial number 
of tumor foci distributed all over the body, tumor burden was sharply reduced 
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Figure 2. Fra-1 is largely dispensable for primary colon tumor growth in vivo. A. 0,5*106 HT29 cells 
with or without Fra-1 knockdown were mixed 1:1 with matrigel and injected subcutaneously into 
severely immune compromised (NOD/SCID IL2γ) mice. Tumor growth was measured by a caliper at 
indicated time points (ncontrol=13, nshFra1-1=12, nshFra1-2=13). B. The weight of tumors harvested 
at the end time point of two independent experiments combined. C. Western blot showing Fra-1 
levels in tumors harvested from mice injected with control or Fra-1-depleted HT29 cells. D. Tumors 
harvested at the end of the experiment were analyzed for the expression of Ki67 and Fra-1 by 
immunostaining (40X).
Error bars represent SEM. Statistics: One-Way ANOVA. * p<0.05, ** p<0.01, *** p<0.001.
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in mice injected with Fra-1-depleted cells (Figure 3A-B). 29 days after injection, 
control mice had a saturated luciferase signal accompanied by severe weight 
loss (Suppl. Fig. 2A). At this time point, the average difference between control 
mice and mice injected with Fra-1-depleted cells was 206-fold. 
 At autopsy, multiple macroscopic tumors were observed on the 
subcutaneous skin and peritoneal wall as well as several organs of the 
control mice such as lung, spine, kidneys, ovaries, lymph nodes, skin and 
muscles in the extremities (Suppl. Fig. 2B). Immunohistochemical staining 
further showed foci in the liver, bones and brain. Much fewer tumors were 
observed in the mice injected with Fra-1-depleted cells, both macroscopically 
and by immunostaining (Figure 3C-D). Importantly, and in contrast to our 
observations for primary tumor growth, in a great majority of the cases, the 
tumor foci formed by Fra-1-depleted cells were positive for Fra-1, sometimes 
in a heterogeneous fashion (Suppl. Fig. 2C, D, E). We observed a similar pattern 
in HCT116 cells, which metastasize preferentially to the liver: Fra-1- depleted 
HCT116 cells formed significantly fewer and smaller foci in the liver upon 
intravenous injection (Suppl. Fig. 1D). Together, these results demonstrate 
that Fra-1 is critical for the metastatic spread of colon cancer cells in vivo, yet 
expendable for primary tumor growth.
Acute Fra-1 depletion impairs growth of established metastatic foci
The results obtained with cells lacking Fra-1 expression suggest an important 
contribution of Fra-1 to the metastatic potential of colon cancer cells. From 
a clinical point of view, it would be more relevant to determine the impact of 
Fra-1 depletion on tumors that have already been established, rather than to 
prevent outgrowth. Therefore, we decided to investigate whether acute loss of 
Fra-1 affects the growth of established tumor foci. This system also allowed 
us to exclude the potential bias where one group of cells may not survive the 
injection procedure or the mechanical stress caused by the blood circulation. 
We used an inducible tet-on system enabling us to deplete Fra-1 on doxycycline 
administration via the drinking water of the mice (Suppl. Fig 3A). To ensure a 
homogeneous level of downregulation of Fra-1 upon doxycycline treatment, 
we generated a cell clone (HT29-C25) harboring the tet-on construct. The 
mice were injected intravenously with control or HT29-C25 cells and each 
group was randomized into two sub-groups at the day of injection. One group 
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continuously received doxycycline in drinking water from day 0 onwards 
after the inoculation of tumor cells, whereas the other was mock-treated. The 
total tumor burden was reduced 56-times in HT29-C25-injected mice upon 
doxycycline treatment (Figure 4A), whereas mice injected with control cells 
had no difference in luciferase signal until the end of the experiment (Suppl. 
Fig. 3B). This result indicates that when Fra-1 knockdown is induced after the 
initial seeding of tumor cells upon intravenous inoculation, Fra-1 is required 
for tumor outgrowth.
 Next, Fra-1 depletion was induced when the tumor burden started 
increasing (after an initial drop as judged by luciferase imaging). Twenty 
days after treatment, Fra-1 depletion caused an eight-fold reduction in tumor 
burden (Figure 4B). Once again, the rate of tumor development was the same 
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Figure 3. Fra-1 is crucial for efficient metastatic spread of colon cancer cells. A. 0,5*106 HT29 
cells were injected intravenously into NSG mice. Tumor expansion was followed by IVIS from 
day0 onwards. Photon flux from two independent experiments was combined. n = 6 mice/group/
experiment. Error bars represent SEM. Statistics: One-Way ANOVA * p<0.05, **p<0.005,****p<0.0001 
B. Representative images of mice at each time point. C-D. GFP staining showing tumor foci in lungs 
and liver.
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in the mice injected with control cells regardless of doxycycline treatment 
(Suppl. Fig. 3C). Similar to the previous experiment (Figure 3), mice injected 
with control cells developed tumors in a broad range of organs, but there 
were very few macroscopically detectable tumors in the HT29-C25-injected 
mice on doxycycline treatment. Also similar to the previous experiment, 
tumors harvested at the end of the experiment showed varying levels of 
Fra-1 suggesting that some tumors were formed by Fra-1-proficient cells 
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Figure 4. Acute Fra-1 depletion impairs growth of established metastatic foci. A-B. 0,5*106 
HT29-C25 cells were intravenously injected into NSG mice. Growth curves of intravenously injected 
HT29-C25 cells with or without doxycycline treatment starting at day0 or day12. C-D. The mice in 
the experiment shown in B were injected with 15mg/kg luciferin five minutes before sacrifice. The 
lungs were harvested and imaged in luciferin-containing PBS and quantified. E. Hematoxylin and 
eosin staining of representative lung sections from mice of experiment shown in B, treated with 
doxycycline or not. The arrowheads point to the tumor foci. 
Error bars represent SEM. Statistics: Non-parametric student’s t-test. **p<0.005,***p<0.001.
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(Suppl. Fig. 3D). As assessed by the luciferase signal, doxycycline-treated mice 
have approximately five times less burden in their lungs compared to mock-
treated mice (Figure 4C-D). These mice had not only fewer but also smaller 
tumor foci in their lungs (Figure 4E). Altogether, these data suggest that Fra-1 
is essential also for growth and expansion of established (micro)metastases of 
colon cancer cells.
Fra-1-regulated gene signature is a prognostic classifier in colon cancer
Based on these findings, which are consistent with, and extend, those of 
others [18, 23, 24], Fra-1 acts as an important pro-metastatic factor in colon 
cancer. Since metastatic relapse is a major reason of cancer-related deaths, 
we asked whether we could stratify colon cancer patients based on Fra-1 
expression levels, similar to what we have shown recently for breast cancer [7]. 
The prognostic value of Fra-1 was assessed by correlating FOSL1  mRNA levels 
(encoding Fra-1) in colon cancer patient samples to disease-free survival in 
five gene expression datasets. We observed that patients with tumors showing 
FOSL1 expression higher than median levels had a significantly worse 
prognosis in the first five years after treatment or surgery (Figure 5A).  
 However, Fra-1 is not an ideal drug target due to the absence of a catalytic 
site that can be readily targeted by a small molecule. The lack of an available 
inhibitor against Fra-1 prompted us to search for critical downstream targets 
of Fra-1 that are involved in metastasis. We compared the expression profiles 
of control and Fra-1-depleted HT29 cells by RNA sequencing and selected the 
genes that are significantly regulated by Fra-1. This classifier contains a total 
of 199 genes, 88 of which are positively regulated by Fra-1 and 111 negatively 
(Suppl. Table 1). 
 According to non-negative matrix factorization (NMF) analysis, colon 
cancer patients could be divided into three prognostic groups based on the 
expression levels of Fra-1-regulated genes. The heat map demonstrates that 
the genes that were positively regulated by Fra-1 are overexpressed in patients 
in subtype 1 and not in subtypes 2 and 3. On the other hand, genes that were 
negatively regulated by Fra-1 have lower expression levels in patients in 
subtype 1 (Figure 5B), independently of tumor stage or dataset (Suppl. Fig. 4). 
A Kaplan-Meier analysis showed that subtypes 2 and 3 are good prognosis 
groups. They only slightly differ from each other in the initial survival rates 
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Figure 5. Fra-1-regulated gene signature is a prognostic classifier in colon cancer. A. Disease free 
survival (DFS) analysis based on FOSL1 expression. Samples were split according to lower or higher 
than average expression of FOSL1. Patients with low expression of FOSL1 exhibited significantly 
longer DFS than patients with higher expression. B. Heat map of the gene expression of the Fra-1 
signature. Gene expression is shown as color gradient from blue (low expression) to yellow (high 
expression). The color bar on the left side indicates direction of regulation in Fra-1 knock-down 
cells. Color bars on top of the heat map show sample stage, source data set and Fra-1KD signature 
cluster, in this order. C. Disease-free survival curve for the three subtypes resulting from hierarchical 
clustering with the Fra-1 signature. Subtype 1 has significantly shorter DFS than subtypes 2 and 3, 
which show no survival difference.
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but in the long term have a similarly good prognosis. Subtype 1, on the other 
hand, has a significantly worse disease-free survival compared to the other 
two groups as well as poorer disease-specific and overall survival (Fig. 5C, 
Suppl. Fig. 5). In a Cox proportional hazards model stratified for gender and 
stage, subtypes 2 and 3 showed significantly better disease-free survival 
(HR = 0.43, p = 4.42*10-5 and HR = 0.51, p= 0.001) than subtype 1. Analyzing 
each stage separately, we found similar effects for each stage albeit with 
different effect size (Table 1). A comparable pattern was observed with disease-
specific and overall survival analysis with the exception of stage 3 patients in 
subtype 3 in case of overall survival (Suppl. Table 2). These data suggest that 
overexpression of genes positively regulated by Fra-1 is correlated with poor 
outcome, whereas the expression of genes negatively regulated by Fra-1 is 
associated with better outcome. Therefore, our Fra-1 classifier has prognostic 
power to predict the clinical outcome of colon cancer patients.
N(n) HR 95% CI p-value
Subtype 1 78 (55) 1
2 228 (42) 0.43 0.28-0.64 0.0000442
3 184 (40) 0.51 0.33-0.77 0.001
Stage 2
N(n) HR 95% CI p-value
Subtype 1 66 (19) 1
2 126 (12) 0.2999 0.15 - 0.68 0.0011
3 97 (15) 0.4902 0.25 - 0.97 0.0393
Stage 3
N(n) HR 95% CI p-value
Subtype 1 52 (27) 1
2 65 (21) 0.5213 0.29 - 0.92 0.0253
3 60 (21) 0.6612 0.37 - 1.17 0.1569
Stage 4
N(n) HR 95% CI p-value
Subtype 1 8 (8) 1
2 11 (8) 0.37 0.13 - 1.03 0.0572
3 8 (4) 0.19 0.05 - 0.71 0.0132
Table 1. Cox Proportional Hazards Model for Disease-Free Survival. Cox proportional hazards 
model estimating hazard ratios for disease-free survival for the subtypes stratified for gender and 
tumor stage.
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Fra-1 regulates the Wnt pathway
The influence of focal adhesions on motility and invasiveness and focal 
adhesion pathway regulation by Fra-1 in colon cancer cells are previously 
reported mechanisms of the pro-metastatic activity of Fra-1 [18, 25]. 
Consistently, Fra-1 knockdown in colon cancer cells decreased the expression 
of a panel of focal adhesion genes, indicating that our classifier is relevant and 
a reliable indicator of the aggressiveness of colon cancer (Figure 6A). 
 On the other hand, regulation of the Wnt pathway by Fra-1 is an 
unexplored phenomenon. The Wnt pathway is significantly represented 
by seven genes in the classifier: whereas Wnt10A, SMAD3, DKK1 and DVL1 
were downregulated upon Fra-1 knockdown, BAMBI, ROCK2 and PLCB4 were 
upregulated (Table 2). Notably, Wnt10A is the most abundantly expressed Wnt 
gene in HT29 cells (Suppl. Fig. 6). We validated Wnt10A, SMAD3, DKK1 and DVL1 
dowregulation by Fra-1 depletion in HT29, and Wnt10A and DVL1 in HCT15 cells 
(Figure 6B-C). We also examined by a luciferase reporter assay whether Fra-1 
depletion modified beta-catenin activity. HT29, HCT15 and DLD-1 cells with or 
without a Fra-1 knockdown were transfected with the TOP/FOP constructs to 
measure transcriptional activity of beta-catenin upon loss of Fra-1 expression. 
We observed an effective reduction in the beta-catenin-mediated transcription 
between control and Fra-1-depleted cells (Figure 7). These data suggest that 
Fra-1 regulates the canonical Wnt signaling by modulating the expression of 
Wnt pathway components and the transcriptional activity of beta-catenin.
Discussion
The high lethality rate of colon cancer is mainly due to recurrence and distant 
metastasis. It therefore is crucial to better understand and predict these 
outcomes in order to take appropriate action with regard to treatment options. 
In this report, we demonstrate that Fra-1 is a critical biological determinant 
of colon cancer metastasis, as judged by two main observations. First, Fra-1 
depletion severely impaired metastatic foci formation of colon cancer cells in 
vivo. Second, gene expression analysis by RNA sequencing of metastatic colon 
cancer cells revealed that a Fra-1 classifier comprising genes significantly 
regulated by Fra-1 is a strong predictor of disease-free survival. 
 Others have previously shown that Fra-1 is responsible for migration of 
colon cancer cells in vitro [18]. We found that Fra-1 is critical for the metastatic 
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Figure 6. Fra-1 regulates the expression of Wnt pathway components. A. Validation of the focal 
adhesion pathway by qRT-PCR upon Fra-1 depletion in HT29 cells. B-C. qRT-PCR analysis of Wnt 
pathway components in the classifier in HT29 and HCT15 cells. 
Error bars represent SEM. Statistics: One_Way ANOVA * p<0.05, ** p<0.01, *** p<0.001,  ****p<0.0001.
Term p value Genes Benjamini
Focal adhesion 0.0021
CAV2, CAV1, LAMB3, LAMA3, ROCK2, ITGA1, 
CAPN2, ITGB1, FLNA, PXN
0.1548
Axon guidance 0.0101
NRP1, ROCK2, ABLIM3, SEMA7A, ROBO2, 
EPHB3, ITGB1
0.1812
Hedgehog signaling pathway 0.0458 BMP4, WNT10A, GLI2, SHH 0.5231
Wnt signaling pathway 0.0648 WNT10A, PLCB4, DKK1, ROCK2, SMAD3, DVL1 0.5302
Leukocyte transendothelial migration 0.0886 ROCK2, NOX1, ESAM, ITGB1, PXN 0.5194
Table 2. KEGG Pathway Analysis. KEGG pathway analysis on the classifier genes reveals Wnt 
pathway as one of the significantly regulated pathways by Fra-1. 
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Figure 7. Fra-1 regulates beta-catenin activity. A. Western blots showing efficient depletion of Fra-1 
in HT29, HCT15 and DLD-1 cells. B-D. Beta-catenin reporter assay on HT29, HCT15 and DLD-1 cells 
upon Fra-1 depletion. Error bars represent SEM. Statistics: One_Way ANOVA * p<0.05, ** p<0.01, *** 
p<0.001,  ****p<0.0001.
spread of colon cancer cells, even after establishment, yet largely dispensable 
for primary tumor growth. The growth rate of subcutaneous xenografts mirrors 
the results of 3D colony formation assays in vitro, showing a significant 
three-fold decrease in growth and colony number, respectively. These results, 
combined with the fact that Fra-1 knockdown was retained until the end of 
the experiment, indicate that Fra-1 is not critically required for primary tumor 
growth, since the tumors still grow in the absence of Fra-1. This differs, for 
example, from our recent observations for DDR kinases, for which shRNAs were 
commonly lost during tumor expansion [26]. In contrast, in an experimental 
metastasis model where the cells are injected intravenously, Fra-1-depleted 
colon cancer cells show a stark defect in their ability to form metastatic foci 
in the mice. The observation that the few tumor foci that could be found in 
the lungs of mice injected with Fra-1 depleted cells were largely Fra-1-positive 
indicate that the tumor burden is mainly caused by Fra-1-proficient cells. 
We did not observe such a negative selection pressure against, nor a similar 
growth disadvantage of, Fra-1-depleted cells in primary tumor growth. These 
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data together suggest that Fra-1 has predominantly a metastasis-related role 
in colon cancer. 
 Metastasis is a stepwise process in which the cells must first 
disseminate from the primary tumor, join the blood stream or the lymphatic 
system by digesting through the stroma and the basement membrane, 
extravasate at a secondary site, and grow out [1, 27]. Since our experimental 
metastasis model bypasses the initial steps of metastasis and the cells 
directly enter the blood circulation upon injection, the difference between 
the metastatic ability of Fra-1-deficient and Fra-1-proficient cells is most 
likely because Fra-1 deficient cells fail at survival in the blood stream or at 
extravasation at a secondary site. By using an inducible system, and therefore 
giving equal chances of survival after inoculation, we tested whether the 
cells would still suffer from an acute loss of Fra-1 after intravenous injection 
and establishment of (micro)metastases. Extravasation and micrometastasis 
formation have been shown to occur within the first 24 hours after inoculation 
[28-30]. In the absence of the support of other cancer cells or a stromal mimic 
like matrigel, HT29 cells depleted of Fra-1 were 56 times less successful in 
forming metastatic tumor foci, resulting in significantly fewer and smaller 
tumor foci in the lungs of the mice. Heterogeneous Fra-1 levels in the tumor 
foci were commonly observed, with many cells showing restoration of Fra-1 
levels, suggesting a negative pressure against Fra-1 knockdown cells. These 
results demonstrate further that Fra-1 is critical for the metastatic growth of 
colon cancer cells. 
 Fra-1 is overexpressed in several cancers [31] and we show that its 
expression correlates with a poor 5-year survival chance of colon cancer 
patients. It has proven difficult to develop inhibitors against transcription 
factors, making Fra-1 an unlikely drug target, even though this could aid in 
improving the treatment options of colon cancer patients. Furthermore, 
expression levels of transcription factors do not necessarily reflect the level 
of their activity. It has been suggested that in a data-driven approach, targets 
acting downstream of a transcription factor, rather than the transcription 
factor itself, possess better distinguishing features, because they reflect the 
activity of the transcription factor [32]. For these reasons, we compared the 
RNA expression profiles of Fra-1 proficient and deficient HT29 cells. We found 
a total of 199 genes significantly regulated by Fra-1. Our Fra-1 classifier is 
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able to stratify colon cancer patients into three groups based on their disease 
outcome: two good (subtypes 2 and 3) and one poor (subtype 1) prognosis 
groups. Consistent with the role of Fra-1 in metastasis, in patients with a poor 
prognosis, genes positively regulated by Fra-1 are overexpressed while genes 
negatively regulated by Fra-1 have a low expression. Based on this classifier, 
disease-free survival rates of patients in subtype 1 are significantly lower than 
those in subtypes 2 and 3. The same pattern is observed for disease-specific 
and overall survival rates, however with less significance most likely owing to 
the fact that this information is only available for a subset of patient samples. 
 Fra-1 is a transcription factor functioning in heterodimers with other 
components of the AP-1 family. We and others have previously shown that 
Fra-1 down-regulation restores epithelial characteristics, including an 
epithelial-like morphology from a mesenchymal-like one, in breast cancer cells 
[7, 22] and colon cancer cells [33]. Moreover, several attempts to classify CRC 
based on gene expression data identified an EMT-related subtype associated 
with poor prognosis [34-37]. However, in colon cancer cell lines, we did not 
observe any change in the morphology, nor in E-cadherin or Vimentin protein 
levels upon Fra-1 depletion. We also failed to find any EMT genes significantly 
regulated in our RNA sequencing data. Furthermore, our colon cancer Fra-1 
classifier has minimal or no overlap with other prognostic classifiers [35-39] 
nor with our Fra-1 breast cancer classifier [7]. Since Fra-1 has hundreds if not 
thousands of target genes, it is conceivable that it regulates several oncogenic 
processes via different mechanisms in different contexts. Furthermore, the 
basal expression pattern of Fra-1 target genes is conceivably not identical 
among different (cancer) tissues. On the other hand, earlier studies comparing 
metastatic to primary tumors to identify prognostic metastasis genes failed 
to identify Fra-1 [40-42], although Fra-1 was found to be upregulated in cancer 
cells compared to normal colon [40].  
 KEGG pathway analysis on this list of genes in the classifier revealed 
the focal adhesion and the Wnt pathways as overrepresented. Focal adhesions 
are known to be regulated by several AP-1 components, including Fra-1 [18, 43]. 
We confirmed the reliability of our results by validating the Fra-1-mediated 
regulation of several genes involved in focal adhesions by qRT-PCR.  While 
expression of AP-1 components has been reported to be regulated by the 
Wnt pathway [10, 12], a reciprocal regulation between the AP-1 transcription 
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factor complex and Wnt signaling has only been shown in an RNA profiling 
study [33] and awaits further validation. Here, we validated that Wnt pathway 
genes such as DKK-1, DVL-1 and Wnt10A are indeed positively regulated by 
Fra-1 in both HT29 and HCT15 colon cancer cell lines. Wnt10A plays an oncogenic 
role in renal cell carcinoma by activating the canonical Wnt pathway [44], 
and has been found to be highly expressed especially in the invasive fronts 
of esophageal cancer [45]. DVL-1 is a scaffolding protein that interacts with 
the Wnt receptor upon ligand binding and prevents the destruction of beta-
catenin, allowing it to be transported to the nucleus and to form a transcription 
factor complex with TCF/LEF [46]. Despite some conflicting reports about 
DKK-1 promoting migration and invasion [47], it is recognized as a tumor 
suppressor and an inhibitor of Wnt signaling [48]. In this context, one would 
expect DKK-1 levels to increase upon depletion of Fra-1. However, since DKK-
1 expression is regulated by beta-catenin [49], reduced beta-catenin activity 
results in reduced DKK-1 levels in Fra-1-depleted colon cancer cells. Although 
we did not see beta-catenin being directly regulated by Fra-1 at the RNA level, 
reporter assays showed that the activity of beta-catenin is decreased upon Fra-
1 depletion. Because beta-catenin is known to regulate EMT and metastasis, it 
is plausible that the pro-metastatic function of Fra-1 is partially dependent on 
beta-catenin activity, which is tightly regulated by the Wnt pathway.  
 In conclusion, we find that Fra-1 is a critical factor in driving metastasis 
of human colon cancer cells in vivo. Furthermore, we show that a Fra-1 
classifier is a highly significant predictor of patient outcome, independent 
of disease stage. We propose that Fra-1-regulated genes may be explored as 
therapeutic targets for colorectal cancer. 
Materials and Methods
Cell Culture
HEK293T and colon cancer cell lines (HT29, HCT116, HCT15, DLD-1, Colo205) 
were cultured in DMEM supplemented with 2mM glutamine and 9% fetal 
bovine serum (Gibco). For lentivirus production, HEK293T cells were refreshed 
with complete medium containing 25 mM chloroquine, transfected with 
8 μg of lentiviral construct and 4 μg of pMDLglpRRE, pHCMV-G, and pRSVrev 
and refreshed in complete medium after 6-8 hours. The lentivirus containing 
supernatant was used to transduce cell lines, followed by antibiotic 
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selection when applicable. shRNA sequences were as follows: shFra-1(1): 
GTAGATCCTTAGAGGTCCT, shFra-1(2): GGCCTGTGCTTGAACCTGA, shFra-1(3): 
TRCN0000019539, shFra-1(4): TRCN0000019541, shFra-1(5): TRCN0000019542 
(TRC Library, Sigma). The shRNAs 1 and 2 against Fra-1 were custom designed 
and cloned into KH vector. The others were cloned in the pLKO-puro vector. 
Fra-1 overexpression plasmid was from the CCSB-Broad lentiviral expression 
library in pLX204-Blast-V5 vector (Thermo Scientific). Luciferase expressing 
cells were generated by HIV-CS-CG-luc construct. shFra-1(2) sequence was 
cloned into pLKO-teton vector to generate the inducible shFra1 construct. Cells 
harboring an empty pLKO-teton vector were used as control. pRL, TOP and FOP 
constructs for the beta-catenin reporter assay were a kind gift from Emile 
Voest, NKI. 2D proliferation assays were carried out by seeding 3*104 cells/
well in 6-well plates (Corning) and stained with crystal violet after 7 days. For 
3D proliferation assays, 2.4*104 cells were seeded in 0,4% low-melting-point 
agarose (Sigma) on 6-well plates (Corning) coated with a 1% agarose layer. 
The plates were stained with crystal violet after 3 weeks and colonies were 
counted by Image J software. Anoikis resistance experiments were performed 
on ultra-low-attachment 6-well plates (Corning). 0.4*106 cells were seeded in 
complete medium. After 6 days, the cells were collected, washed, trypsinized, 
resuspended in complete medium and counted, or were collected and lysed for 
total protein measurement. 
Beta-catenin reporter assay
The cells were seeded on 24-well plates (Costar) at 1*105 cells/well and co-
transfected with 100ng of TOP or FOP constructs and 10ng of pRL using 
Lipofectamine 3000 reagent (Invitrogen) following manufacturers instructions. 
48 hours after transfection, the cells were lysed and luciferase signals 
were measured in triplicates by dual-luciferase reporter assay (Promega). 
Transfection efficiencies were normalized by dividing the firefly luciferase 
signal by renilla luceriferase signal for each well. TOP/FOP ratio was calculated 
by dividing luciferase signal from TOP-transfected cells to FOP-transfected 
cells. 
Immunoblot analysis and antibodies
Cells were harvested by scraping in cold PBS and the pellets were lysed in 
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RIPA buffer (50 mM TRIS pH 8.0, 150 mM NaCl, 1% Nonidet P40, 0.5% sodium 
deoxycholate, 0.1% SDS, complete protease inhibitor cocktail (Roche), and 
phosphatase inhibitors 10 mM NaF, 1 mM Na3VO4, 1 mM sodium pyrophosphate, 
10 mM beta-glycerophosphate). After centrifugation the protein concentrations 
were determined by Bio-Rad protein assay (Bio-Rad). Immunoblot analysis 
was performed by using 4-12% Bis-Tris polyacrylamide-SDS gels (NuPAGE) and 
transferring these on to nitrocellulose membranes (Amersham). Membranes 
were blocked in 4% skimmed milk powder dissolved in 0.2% Tween-containing 
PBS and incubated with primary antibodies followed by secondary antibodies 
(Invitrogen). Primary antibodies used were Fra-1 (sc-605, Santa Cruz 
Biotechnology), human-specific Fra-1 (sc-28310, Santa Cruz Biotechnology), 
beta-actin (A5316, Sigma), Hsp90 (sc-7947, Santa Cruz Biotechnology). 
qRT-PCR primers
Total RNA was isolated by harvesting the cells in Trizol (Invitrogen) 6 days 
after lentivirus transduction and extracting RNA by subsequent chloroform, 
isopropanol and ethanol treatments. Following DNase treatment for 1 hour 
at 37°C, cDNA was prepared by a reverse transcriptase kit (Invitrogen). The 
average values obtained from two independent experiments are presented.
The primer sequences are as follows:
 Wnt10A forward GGAGACTCGCAACAAGATCC
   reverse  AAAGCGCTCTCTCGGAAAC    
 DKK-1  forward CCTTGGATGGGTATTCCAGA    
   reverse  CCGGAGACAAACAGAACCTT    
 DVL-1  forward GAGCTTGAGTCCAGCAGCTT 
   reverse  CGGATGAGTCTGGATGAGGT 
 SMAD3  forward ACACCAAGTGCATCACCATC 
   reverse  GCGGCAGTAGATGACATGAG 
 PXN  forward GCACAATCCTTGACCCCTTA    
   reverse  GAGCCGTACACAGGTGATGA    
 FLNA  forward AGCCTCAACGTCACCTATGG    
   reverse  ACTTGACCTTGGACGCATCT    
 ITGB2  forward TTCTCCAGAAGGTGGTTTCG
   reverse  AGCAGCCGTGTAACATTCCT
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Survival analysis
From the Gene Expression Omnibus, we downloaded five publicly available data 
sets (GSE17536 [41], GSE17537 [41], GSE14333 [42], GSE33113 [50] and GSE37892) 
with gene expression data from primary CRC samples. Samples contained 
in both GSE14333 and GSE17536 were removed from GSE14333. Disease-free 
survival and staging information was available for a total of 578 tumor samples 
contained in these data sets. Disease-specific survival and overall survival 
were only available for datasets GSE17536 and GSE17537, totaling 232 tumors. 
Differences in survival times were analyzed using the Mantel-Cox log-rank 
test as implemented in the survival package. We performed survival analysis 
combining all stages stratified by stage and gender, and stage-specific survival 
analysis.
 
RNA sequencing and Generation of the Fra-1 classifier
Fra-1 was depleted from HT29 cells with two independent short hairpins. RNA 
was isolated by using Trizol and sequenced on a HiSeq 2000 System (Illumina). 
Data are available at NCBI Gene Expression Omnibus with the accession 
number GSE69415 (http://www.ncbi.nlm.nih.gov). Data were analyzed using 
the R statistical environment [49]. Illumina sequencing data was processed 
using DESeq version 1.12 [49]. We derived a Fra-1 knockdown (Fra-1KD) gene 
expression signature comparing RNA sequencing data from HT29 cell lines 
without and with shRNA knockdown of Fra-1. Knockdown was performed 
using two different hairpins in triplicate. In total, three samples of the wild 
type cell line and two knockdown samples (each with a different hairpin) 
were sequenced. Genes were selected as differentially expressed if they were 
differentially expressed between wild type and Fra-1KD cells but not between 
replicates. Nominal p-values were corrected for multiple testing using the 
Benjamini-Hochberg procedure and corrected p-values < 0.1 were regarded 
as significant. We applied the Fra-1KD signature to the independent data set 
consisting of 578 samples described above. More specifically, we used non-
negative matrix factorization (NMF) as implemented in the NMF package for 
R [53] to cluster the samples into three subtypes. We compared diseases free 
survival between these clusters as described above. 
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Tumor Xenografts and Bioluminescence Analysis
All animal work was done in accordance with a protocol approved by 
the Netherlands Cancer Institute Animal Experiment Ethics Committee. 
Female NOD/SCID/IL2gamma mice aged 5-8 weeks were used for all in vivo 
experiments. 0,5*106 cells were injected into the lateral tail vein in 150 ul PBS 
or subcutaneously into both flanks in a 100 ul 1:1 mixture of growth factor 
reduced matrigel and complete medium. Subcutaneous tumors were manually 
measured twice weekly by a caliper. For bioluminescence imaging, the mice 
were intraperitoneally injected with 15 mg/kg D-luciferin (Caliper Life Sciences) 
15 minutes prior to imaging. The mice were anaesthetized and imaged with 60 
seconds of exposure time (binning=8). Tumor burden in individual organs were 
quantified by injecting the mice with D-luciferin five minutes prior to sacrifice, 
harvesting the organs and imaging in a PBS-luciferin mixture. The data was 
analyzed by Living Image software. For shFra-1 induction, mice were treated 
with 2 mg/ml doxycycline in drinking water containing 10mg/ml sucrose.
Immunohistochemistry
Histological sections and hematoxylin-eosin staining were performed using 
standard procedures. Paraffin sections were deparaffinized, rehydrated, 
pretreated in 0.1 mM sodium citrate pH 6.0, washed and incubated with 
peroxide. The tissue was incubated with primary antibodies for Fra-1 (1:200, sc-
28310, Santa Cruz Biotechnology) or GFP (1:2000, Abcam). Secondary antibody 
was PowerVision (DPVB-999HRP, ImmunoLogic). Peroxidase activity was 
detected with Liquid DAB (K3468, DAKO).
Statistical analysis
Comparisons of two experimental groups were analyzed with two-tailed 
student’s t-test. One-Way ANOVA corrected for multiple comparisons (Holm-
Sidak) was used to compare more than two experimental groups (Prism; 
GraphPad Software). Error bars represent standard error of the mean (SEM).
Multivariate analysis was performed by fitting a Cox proportional hazards 
model to estimate hazard ratios for the subtypes by stratifying for gender and 
tumor stage.
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Supplementary Figure 1. A. Western blot of Colo205 cells overexpressing Fra-1. B. Colo205 cells with 
or without Fra-1 overexpression were seeded in triplicate into 0,3% agar suspension on top of a 1% 
agar base in 6-well plates at 24,000 cells/well. After three weeks, colonies were stained with crystal 
violet and counted by Image J software. C. Colo205 cells with or without Fra-1 overexpression were 
seeded in triplicate into 6-well ultra-low-attachment plates. 6 days later, the cells were harvested, 
lysed and total protein concentrations were measured. D. 0,5*106 HCT116 cells were injected 
intravenously into NSG mice (ncontrol=4, nshFra-1(1)=5, nshFra-1(2)=5). 5 weeks after injection, the 
mice were sacrificed and organs were harvested. Tumor foci in the livers were manually counted on 
H&E stained sections. Error bars represent SEM. Statistics: One-Way ANOVA * p<0.05
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Supplementary Figure 2. A. Average weight of the mice in each group. B. Images of mice 
showing macroscoprically visible tumors on the subcutaneous skin and peritoneal wall. C. Fra-1 
immunostaining on representative lung sections of mice injected with control or Fra-1-depleted 
cells. D. Western blots on tumors harvested from two representative mice injected with Fra-1-
depleted cells. E. Fra-1 staining on tumor sections. Upper panel shows a Fra-1 positive control tumor. 
Lower panels show two tumors from the same mouse stained together on the same slide with 
heterogeneous Fra-1 staining. 
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Supplementary Figure 3. A. Western blot 
showing C25 cells downregulating Fra-1 
upon induction with doxycycline for 2, 4 and 
6 days in vitro. B-C. Quantification of tumor 
expansion in mice injected with control cells 
and treated with doxycycline or not (n=6 per 
group). D. Western blots of tumors harvested 
from mice injected with C25 cells and treated 
with doxycycline or not.
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Supplementary Figure 4. The heterogeneity of the three subtypes with regard to tumor stage and 
dataset is shown in color coded bars.
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Supplementary Figure 5. A. Disease-specific survival curve for the three subtypes resulting from 
hierarchical clustering with the Fra-1 signature. B. Overall survival curve for the three subtypes 
resulting from hierarchical clustering with the Fra-1 signature.
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Supplementary Figure 6. Normalized read counts of all Wnt genes found to be expressed in HT29 
cells with or without Fra-1 depletion.
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Ensembl ID Gene Symbol Entrez ID Fold Difference (log2) FDR
ENSG00000144821 MYH15 22989 1.7556 9.40E-02
ENSG00000175592 FOSL1 8061 1.456 3.32E-06
ENSG00000123843 C4BPB 725 1.4271 1.41E-04
ENSG00000137440 FGFBP1 9982 1.3543 7.38E-04
ENSG00000107984 DKK1 22943 1.3463 1.89E-03
ENSG00000153292 GPR110 266977 1.3443 1.55E-05
ENSG00000214049 UCA1 652995 1.3021 1.32E-02
ENSG00000092929 UNC13D 201294 1.2329 4.58E-04
ENSG00000181126 HLA-V NA 1.2052 7.99E-02
ENSG00000105974 CAV1 857 1.1673 8.53E-03
ENSG00000185567 AHNAK2 113146 1.146 7.84E-03
ENSG00000120708 TGFBI 7045 1.1016 4.50E-04
ENSG00000070404 FSTL3 10272 1.0556 2.35E-02
ENSG00000137878 GCOM1 145781 1.0251 5.31E-02
ENSG00000138623 SEMA7A 8482 0.9786 2.82E-02
ENSG00000075461 CACNG4 27092 0.9638 4.22E-04
ENSG00000111348 ARHGDIB 397 0.9593 5.79E-02
ENSG00000099250 NRP1 8829 0.9079 7.41E-03
ENSG00000196352 CD55 1604 0.9071 2.43E-09
ENSG00000167767 KRT80 144501 0.8855 5.97E-03
ENSG00000188042 ARL4C 10123 0.883 2.43E-02
ENSG00000167779 IGFBP6 3489 0.8526 3.15E-04
ENSG00000134954 ETS1 2113 0.8485 6.78E-04
ENSG00000177469 PTRF 284119 0.8171 1.75E-09
ENSG00000124225 PMEPA1 56937 0.8008 7.05E-04
ENSG00000147394 ZNF185 7739 0.783 3.05E-03
ENSG00000073756 PTGS2 5743 0.7782 3.15E-04
ENSG00000196154 S100A4 6275 0.7772 9.12E-02
ENSG00000117472 TSPAN1 10103 0.7478 2.72E-05
ENSG00000138119 MYOF 26509 0.7364 3.21E-04
ENSG00000154102 C16orf74 404550 0.7277 1.24E-02
ENSG00000114455 HHLA2 11148 0.7268 3.59E-02
ENSG00000150687 PRSS23 11098 0.674 1.41E-04
ENSG00000172927 MYEOV 26579 0.6616 3.94E-04
ENSG00000074047 GLI2 2736 0.6557 3.85E-02
ENSG00000171435 KSR2 283455 0.6521 2.89E-02
ENSG00000149564 ESAM 90952 0.6386 9.30E-02
ENSG00000164120 HPGD 3248 0.6218 1.70E-04
ENSG00000057019 DCBLD2 131566 0.6158 8.36E-03
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Ensembl ID Gene Symbol Entrez ID Fold Difference (log2) FDR
ENSG00000103187 COTL1 23406 0.6093 7.71E-02
ENSG00000154217 PITPNC1 26207 0.5927 2.90E-04
ENSG00000088367 EPB41L1 2036 0.5848 1.80E-04
ENSG00000053747 LAMA3 3909 0.5819 7.84E-03
ENSG00000197757 HOXC6 3223 0.5722 5.55E-02
ENSG00000198825 INPP5F 22876 0.5694 4.95E-02
ENSG00000099810 MTAP 4507 0.5665 1.88E-03
ENSG00000197747 S100A10 6281 0.5648 3.05E-03
ENSG00000105971 CAV2 858 0.5647 5.37E-02
ENSG00000165388 ZNF488 118738 0.5596 1.45E-02
ENSG00000085788 DDHD2 23259 0.5557 5.98E-03
ENSG00000125378 BMP4 652 0.5449 7.41E-03
ENSG00000128567 PODXL 5420 0.537 3.38E-02
ENSG00000253368 TRNP1 388610 0.5345 8.02E-04
ENSG00000173210 ABLIM3 22885 0.5305 1.51E-02
ENSG00000205542 TMSB4X 7114 0.5246 1.60E-02
ENSG00000168785 TSPAN5 10098 0.5246 3.45E-02
ENSG00000142178 SIK1 150094 0.5221 9.93E-02
ENSG00000184916 JAG2 3714 0.5192 6.80E-02
ENSG00000225485 ARHGAP23 57636 0.5175 4.22E-04
ENSG00000107404 DVL1 1855 0.514 6.23E-03
ENSG00000188910 GJB3 2707 0.507 7.41E-03
ENSG00000127564 PKMYT1 9088 0.5041 2.96E-02
ENSG00000150782 IL18 3606 0.4957 2.37E-02
ENSG00000139211 AMIGO2 347902 0.4905 3.32E-03
ENSG00000118898 PPL 5493 0.4725 9.34E-03
ENSG00000100605 ITPK1 3705 0.4672 6.04E-03
ENSG00000106078 COBL 23242 0.4614 1.90E-02
ENSG00000162836 ACP6 51205 0.4499 1.87E-02
ENSG00000204619 PPP1R11 6992 0.4414 3.63E-02
ENSG00000196924 FLNA 2316 0.4402 7.84E-03
ENSG00000100504 PYGL 5836 0.4317 1.90E-02
ENSG00000135925 WNT10A 80326 0.426 5.55E-02
ENSG00000089159 PXN 5829 0.4138 1.90E-02
ENSG00000102007 PLP2 5355 0.4135 2.96E-02
ENSG00000141562 NARF 26502 0.4098 8.69E-02
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Ensembl ID Gene Symbol Entrez ID Fold Difference (log2) FDR
ENSG00000019505 SYT13 57586 0.3881 2.91E-02
ENSG00000198742 SMURF1 57154 0.3856 5.86E-02
ENSG00000196878 LAMB3 3914 0.3796 7.99E-02
ENSG00000150093 ITGB1 3688 0.3786 3.57E-02
ENSG00000131981 LGALS3 3958 0.3637 5.79E-02
ENSG00000152492 CCDC50 152137 0.3617 5.81E-02
ENSG00000162909 CAPN2 824 0.3579 6.70E-02
ENSG00000137309 HMGA1 3159 0.3572 4.95E-02
ENSG00000187109 NAP1L1 4673 0.3547 5.55E-02
ENSG00000187678 SPRY4 81848 -0.3772 8.42E-02
ENSG00000131389 SLC6A6 6533 -0.3927 5.11E-02
ENSG00000170145 SIK2 23235 -0.3932 4.65E-02
ENSG00000115993 TRAK2 66008 -0.3941 9.39E-02
ENSG00000106546 AHR 196 -0.4006 8.69E-02
ENSG00000134352 IL6ST 3572 -0.4087 3.45E-02
ENSG00000173702 MUC13 56667 -0.4091 7.21E-02
ENSG00000165156 ZHX1 11244 -0.4146 3.63E-02
ENSG00000134318 ROCK2 9475 -0.4164 3.45E-02
ENSG00000188559 RALGAPA2 57186 -0.4261 2.43E-02
ENSG00000145703 IQGAP2 10788 -0.4438 4.03E-02
ENSG00000085831 TTC39A 22996 -0.4583 7.48E-02
ENSG00000175311 ANKS4B 257629 -0.4642 9.30E-02
ENSG00000123636 BAZ2B 29994 -0.468 5.47E-02
ENSG00000021300 PLEKHB1 58473 -0.4681 2.43E-02
ENSG00000106351 AGFG2 3268 -0.4725 6.77E-02
ENSG00000111266 DUSP16 80824 -0.4808 5.37E-02
ENSG00000185127 C6orf120 387263 -0.4829 3.11E-02
ENSG00000184500 PROS1 5627 -0.4836 8.56E-03
ENSG00000116704 SLC35D1 23169 -0.4844 5.27E-02
ENSG00000126217 MCF2L 23263 -0.486 2.37E-02
ENSG00000177707 PVRL3 25945 -0.487 1.87E-02
ENSG00000161011 SQSTM1 8878 -0.4872 4.90E-02
ENSG00000170759 KIF5B 3799 -0.4895 1.88E-03
ENSG00000064270 ATP2C2 9914 -0.4905 7.47E-02
ENSG00000121064 SCPEP1 59342 -0.4927 8.34E-02
ENSG00000162174 ASRGL1 80150 -0.5113 1.86E-02
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Ensembl ID Gene Symbol Entrez ID Fold Difference (log2) FDR
ENSG00000145569 FAM105A 54491 -0.536 1.43E-02
ENSG00000077150 NFKB2 4791 -0.5559 1.77E-02
ENSG00000143153 ATP1B1 481 -0.561 1.05E-02
ENSG00000139318 DUSP6 1848 -0.562 6.52E-04
ENSG00000105854 PON2 5445 -0.5791 6.23E-03
ENSG00000148468 FAM171A1 221061 -0.5953 8.69E-02
ENSG00000164690 SHH 6469 -0.5961 7.21E-02
ENSG00000155629 PIK3AP1 118788 -0.6061 1.89E-03
ENSG00000169994 MYO7B 4648 -0.6141 2.79E-02
ENSG00000146802 TMEM168 64418 -0.6174 1.49E-04
ENSG00000164761 TNFRSF11B 4982 -0.6207 4.27E-02
ENSG00000234155 NA -0.6213 3.85E-02
ENSG00000101333 PLCB4 5332 -0.6525 5.39E-02
ENSG00000170345 FOS 2353 -0.6596 6.52E-02
ENSG00000150961 SEC24D 9871 -0.6656 2.71E-03
ENSG00000138640 FAM13A 10144 -0.6767 1.48E-03
ENSG00000067113 PPAP2A 8611 -0.6779 1.32E-02
ENSG00000257743 NA -0.6798 3.05E-03
ENSG00000168916 ZNF608 57507 -0.6803 4.65E-02
ENSG00000153071 DAB2 1601 -0.684 5.55E-02
ENSG00000069869 NEDD4 4734 -0.693 6.52E-02
ENSG00000172164 SNTB1 6641 -0.7117 1.43E-02
ENSG00000149212 SESN3 143686 -0.7138 5.85E-04
ENSG00000157388 CACNA1D 776 -0.7145 2.96E-02
ENSG00000072201 LNX1 84708 -0.7272 6.23E-02
ENSG00000081803 CADPS2 93664 -0.7289 3.45E-02
ENSG00000182489 XKRX 402415 -0.7472 1.24E-02
ENSG00000143416 SELENBP1 8991 -0.7594 1.28E-03
ENSG00000182580 EPHB3 2049 -0.7647 8.24E-04
ENSG00000123104 ITPR2 3709 -0.7733 3.57E-02
ENSG00000250722 SEPP1 6414 -0.7942 6.57E-02
ENSG00000110492 MDK 4192 -0.8022 6.74E-04
ENSG00000214290 C11orf93 120376 -0.8089 2.13E-02
ENSG00000165359 DDX26B 203522 -0.8128 4.90E-02
ENSG00000079385 CEACAM1 634 -0.8289 5.55E-02
ENSG00000168961 LGALS9 3965 -0.8363 2.85E-02
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Ensembl ID Gene Symbol Entrez ID Fold Difference (log2) FDR
ENSG00000114541 FRMD4B 23150 -0.8717 4.38E-04
ENSG00000167588 GPD1 2819 -0.8876 7.99E-02
ENSG00000225329 NA -0.9024 6.78E-04
ENSG00000187134 AKR1C1 1645 -0.9215 4.72E-03
ENSG00000170608 FOXA3 3171 -0.9292 5.55E-02
ENSG00000007952 NOX1 27035 -0.9653 3.57E-02
ENSG00000049192 ADAMTS6 11174 -0.9711 2.35E-02
ENSG00000196139 AKR1C3 8644 -0.9803 4.15E-02
ENSG00000150893 FREM2 341640 -0.9818 3.81E-03
ENSG00000213949 ITGA1 3672 -1.0002 1.74E-06
ENSG00000137251 TINAG 27283 -1.0058 9.00E-04
ENSG00000095739 BAMBI 25805 -1.0344 3.32E-06
ENSG00000137699 TRIM29 23650 -1.0621 2.92E-02
ENSG00000107957 SH3PXD2A 9644 -1.0999 3.49E-02
ENSG00000152580 IGSF10 285313 -1.1255 5.86E-05
ENSG00000259974 LINC00261 140828 -1.228 1.83E-02
ENSG00000132329 RAMP1 10267 -1.2367 5.55E-02
ENSG00000106069 CHN2 1124 -1.2394 5.86E-05
ENSG00000122176 FMOD 2331 -1.2434 9.30E-02
ENSG00000197249 SERPINA1 5265 -1.2435 1.76E-02
ENSG00000031081 ARHGAP31 57514 -1.2731 1.85E-02
ENSG00000111885 MAN1A1 4121 -1.2758 1.66E-03
ENSG00000196167 C11orf92 NA -1.3793 8.31E-02
ENSG00000132561 MATN2 4147 -1.4006 2.75E-02
ENSG00000132561 MATN2 100506558 -1.4006 2.75E-02
ENSG00000165092 ALDH1A1 216 -1.4059 3.63E-02
ENSG00000014257 ACPP 55 -1.4389 6.81E-04
ENSG00000222033 NA -1.4424 5.56E-03
ENSG00000166922 SCG5 6447 -1.5011 9.30E-02
ENSG00000090920 FCGBP 8857 -1.5325 7.41E-03
ENSG00000185477 GPRIN3 285513 -1.5435 2.30E-02
ENSG00000151632 AKR1C2 1646 -1.6432 2.56E-03
ENSG00000151632 AKR1C2 101060798 -1.6432 2.56E-03
ENSG00000173467 AGR3 155465 -1.7722 2.14E-03
ENSG00000165029 ABCA1 19 -1.9713 8.24E-04
ENSG00000183091 NEB 4703 -2.0371 1.74E-06
Supplementary Table 1. List of genes in the classifier.
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N(n) HR 95% CI p-value
Subtype 1 55 (24) 1
2 99 (25) 0.49 0.28 - 0.89 0.02
3 78 (21) 0.74 0.39 - 1.39 0.35
Stage 2
N(n) HR 95% CI p-value
Subtype 1 19 (5) 1
2 28 (0) NA
3 25 (4) 0.68 0.17 - 2.72 0.58
Stage 3
N(n) HR 95% CI p-value
Subtype 1 19 (8) 1
2 32 (5) 0.28 0.09 - 0.87 0.03
3 25 (6) 0.66 0.23 - 1.93 0.45
Stage 4
N(n) HR 95% CI p-value
Subtype 1 14 (11) 1
2 25 (19) 0.8 0.37 - 1.73 0.58
3 17 (11) 0.68 0.289 - 1.61 0.38
Supplementary Table 2. A. Cox Proportional Hazards Model for Disease-Specific Survival
B. Cox Proportional Hazards Model for Overall Survival
A.
B.
N(n) HR 95% CI p-value
Subtype 1 55 (31) 1
2 99 (34) 0.52 0.32 - 0.86 0.01
3 78 (28) 0.68 0.40 - 1.16 0.15
Stage 2
N(n) HR 95% CI p-value
Subtype 1 19 (10) 1
2 28 (2) 0.15 0.03 - 0.68 0.01
3 25 (4) 0.3 0.09 - 0.99 0.05
Stage 3
N(n) HR 95% CI p-value
Subtype 1 19 (9) 1
2 32 (7) 0.36 0.14 - 0.98 0.05
3 25 (12) 1.19 0.50 - 2.84 0.7
Stage 4
N(n) HR 95% CI p-value
Subtype 1 14 (12) 1
2 25 (21) 0.76 0.37 - 1.55 0.455
3 17 (12) 0.62 0.28 - 1.39 0.248
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Abstract
Fos-related antigen 1 (Fra-1) is a transcription factor overexpressed in multiple 
types of cancers and has been shown to control metastasis in vitro and in 
vivo. We have previously shown that Fra-1 is a major regulator of metastasis 
in breast and colon cancer, and classifiers composed of Fra-1-regulated 
genes in each cancer type are able to predict disease prognosis in patients. 
Here we show data suggesting that Fra-1 itself is a prognostic factor in, and 
a functional determinant of, bladder cancer metastasis. Downregulating or 
knocking out Fra-1 by CRISPR in metastatic bladder cancer cell lines result 
in loss of aggressive characteristics. Fra-1-deficient bladder cancer cells form 
fewer colonies in soft agar and show reduced invasive capacity in vitro. Also 
in vivo, these cells lead to a significantly less tumor burden in an experimental 
metastasis setting. We suggest that Fra-1 is a key factor for bladder cancer.
Introduction
Urothelial bladder cancer (UBC) develops in two ways: papillary UBC that has 
a high recurrence rate but only rarely evolves into high-grade cancer, and non-
papillary muscle-invasive bladder cancer (MIBC) [1]. 30% of the newly diagnosed 
cases are MIBC, which has a poor outcome [2]. Due to its heterogeneous nature, 
there is a lack of (targeted) therapy options for MIBC, making it a major cause 
of cancer-related deaths worldwide. The standard treatment for bladder cancer 
for over three decades has been radical surgery and chemotherapy treatment. 
Based on the disease stage, overall survival upon radical surgery ranges from 
49% to 74%. Cisplatin-based neoadjuvant chemotherapy is the best solution 
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available for MIBC patients [3] and yet it improves the overall survival rate 
only by 6% [4]. Furthermore, biomarkers for early detection, characterization 
or prognostic prediction of MIBC are scarce. Potential markers such as FGFR3, 
p53, survivin and MCM2 or gene classifiers have so far failed or provided 
contradictory information [5].  It therefore is of great importance to identify 
molecules that reliably characterize and/or predict disease outcome. 
 Metastasis is the main reason of cancer-related deaths and remains a 
poorly understood process [6]. The metastatic cascade has several steps such 
as dissemination from the primary tumor, intravasation into the vasculature, 
extravasation and colonization at a secondary site [6, 7]. It is a very dynamic 
and complex mechanism regulated by dozens of genes and involving many 
stromal factors [8]. One of the well-known regulators of metastasis is the 
activator protein 1 (AP-1) complex formed by the Fos (c-Fos, FosB, Fra-1, 
Fra-2) and Jun (c-Jun, JunB and JunD) families of transcription factors [9]. 
Fra-1 is one of the transcription factors of the Fos family which is known to 
regulate a large variety of genes involved in proliferation, survival, migration 
and differentiation [10]. Among all Fos family members, Fra-1 is the most 
frequently overexpressed factor in different human cancers [11]. For several 
cancer types, high Fra-1 levels are correlated with morphological changes, 
thereby enhancing motility and invasion of cancer cells [9, 12]. We have 
previously shown that Fra-1 is a major regulator of metastasis in breast and 
colon cancer, and that expression levels of Fra-1-regulated genes successfully 
predict patient survival [13-15]. Also for bladder cancer, Fra-1 has been shown 
to regulate motility in vitro via AXL [16]. In this study, we assessed Fra-1 as 
a prognostic factor in bladder cancer and investigated the role of Fra-1 in 
metastasis of bladder cancer cells in vitro and in vivo. 
Results
Fra-1 has prognostic power and is crucial for outgrowth of bladder 
cancer colonies
Since we have previously demonstrated the prognostic power of Fra-1 in breast 
and colon cancers [13, 14], we tested the ability of Fra-1 itself to stratify bladder 
cancer patients. Based on Fra-1 expression levels alone, bladder cancer patients 
could be stratified in good and poor groups  (Figure 1A). This finding led us to 
investigate the role of Fra-1 in bladder cancer further. We depleted Fra-1 in 
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three bladder cancer cell lines and investigated the changes in their capacity 
to grow colonies in soft agar. In all three cell lines, there was a severe reduction 
in colony outgrowth (Figure 1B-C). This finding indicates a critical role for Fra-
1 in anchorage-independent growth of bladder cancer cells in vitro. Together 
with the fact that Fra-1 expression levels can determine the disease outcome 
of bladder cancer patients, these data reveal Fra-1 both as potential biomarker, 
and important biological determinant, of aggressive bladder cancer.
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Figure1. Fra-1 is crucial for colony outgrowth of bladder cancer cell lines. A. Kaplan-Meier survival 
curves showing bladder cancer patients expressing high (red) or low (blue) levels of Fra-1. B. Western 
blots showing efficient knock-down of Fra-1 in three bladder cancer cell lines with two independent 
shRNAs. Actin serves as loading control. C. Bladder cancer cells with or without Fra-1 knockdown 
were seeded in duplicates in 0,3% agar suspension on top of a 1% agar base in 6-well plates at 24000 
cells/well. After three weeks, plates were scanned and colonies counted by Image J software.
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Fra-1 depletion impairs efficient metastatic spread of bladder cancer 
cells
We next aimed to determine the role of Fra-1 in bladder cancer metastasis in 
vivo. We injected Fra-1-depleted VmCub1 cells intravenously into NSG mice 
and monitored tumor expansion via a luciferase-dependent in vivo imaging 
system. Compared with the mice injected with cells carrying a control 
construct, mice injected with Fra-1-depleted cells had significantly reduced 
tumor burden (Figure 2A). Especially in liver and lungs, where the majority 
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Figure 2. Fra-1 depletion impairs efficient metastatic spread of bladder cancer cells A. 0,5*106 
VmCub1 cells harboring control or Fra-1 shRNAs were injected intravenously into NSG mice. Tumor 
expansion was followed by IVIS afrom day0 onwards. n = 6 mice/group/experiment. B. Number of 
tumor foci was manually counted on hematoxylin and eosin staining of liver sections. Error bars 
represent SEM. Statistics: One-Way ANOVA. *p<0.05, **p<0.005 C. GFP, Ki67 and cleaved caspase-3 
(10x) staining on lung sections.
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of tumor foci were macroscopically visible in the control mice, we observed a 
sharp decrease in the number of foci (Figure 2B-C). Ki67 and cleaved caspase-3 
staining were used as markers of proliferation and apoptosis, respectively. 
These showed no difference between the tumor foci found in the control mice 
compared to the foci in mice injected with Fra-1-depleted cells, suggesting 
that the loss of metastatic ability upon Fra-1 depletion is not due to decreased 
proliferation or increased apoptosis (Figure 2C). Also, when GFP-expressing 
T24 cells were injected intravenously, there were multiple tumor foci in the 
lungs of control mice whereas the mice injected with cells harboring shRNAs 
targeting Fra-1 had virtually none (Suppl. Fig. 1A). These data suggest that Fra-
1 is crucial for bladder cancer metastasis in vivo.
Fra-1 loss diminishes metastatic ability of bladder cancer cells in vivo
Due to the considerable variation of the effect of the two shRNAs in our in 
vivo system (Figure 2A) and the potential interference of shRNA loss with the 
observed metastatic activity of the cells harboring shFra-1 constructs, we next 
sought to investigate the effects of complete Fra-1 loss on the metastasis of 
bladder cancer. For this approach we used a lentiviral CRISPR-Cas9 system 
to knock Fra-1 out and generated sub-clones by expanding single knockout 
cells. We next assessed the ability of these sub-clones to proliferate, invade 
and grow in anchorage-independent conditions, and expand in vivo (Figure 
3A, Suppl. Fig. 1B). We picked one sub-clone from each cell line: VmC-C3 and 
T24-C5. Neither one of these clonal cell lines showed a proliferation defect in 
vitro, however they both had reduced invasive capacity, and VmC-C3 cells had 
a substantial decrease in colony outgrowth under anchorage-independent 
conditions (Fig. 3B, Suppl. Fig. 1C). In vivo, we observed a 155-fold reduction in 
the tumor burden of mice injected with VmC-C3 cells compared with control 
mice. Importantly, this difference is much higher than what we observed with 
the hairpins, indicating that the shRNAs were either not fully effective or were 
lost during the experiment resulting in metastatic expansion (Figure 2A). 
Notably, T24-C5 cells showed no tumor-forming ability in vivo (Suppl. Fig. 1D).
Discussion
90% of cancer mortality is due to metastasis, highlighting the importance of 
predicting disease progression and developing relevant treatment strategies 
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Figure 3. Fra-1 loss diminishes metastatic ability of bladder cancer cells in vivo. A. VmCub1 cells 
were transduced with a lentiviral CRISPR vector harboring a guide RNA targeting Fra-1. The cells 
were then seeded at a very low density on 10cm culture dishes. Emerging colonies were isolated and 
expanded separately. Fra-1 levels of the control- and sgFra-1-transduced cells, and the single-cell 
clones are shown on Western blot. Hsp90 serves as loading control. B. Control or VmC-C3 cells were 
seeded on 6-well plates for proliferation, 6-well matrigel-coated boyden chambers for invasion, and 
0,3% agar suspension on top of a 1% agar base in 6-well plates. The cells were stained with crystal 
violet after seven days, two days, or three weeks, respectively. C. 0,5*106 control or VmC-C3 cells 
were injected into the tail vein of NSG mice. Tumor expansion was followed by IVIS from day0 
onwards. Error bars represent SEM. Statistics: Two-tailed t-test. ** p<0.01, *** p<0.001, ****p<0.0001 
D. Representative images of mice at each time point.
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[6]. Bladder cancer especially lacks effective biomarkers that can allow 
detection of aggressive urothelial carcinoma at an early stage. In this study 
we show that Fra-1 can be used as a prognostic marker and demonstrate that 
Fra-1 is an important regulator of bladder cancer metastasis in vitro and in 
vivo. 
 We have recently shown a functional and prognostic role of 
Fra-1 in metastasis of breast and colon cancers [13, 14]. These properties of 
Fra-1 are shared also with bladder cancer. We found that Fra-1-high bladder 
cancer patients have a significantly worse prognosis compared to Fra-1-low 
patients. Together with the previous implication of Fra-1 in bladder cancer cell 
motility [16], this data suggests that Fra-1 has a similar role to that in breast 
and colon cancers. Indeed, compared to control cells, Fra-1 depletion led to 
2- to 3-fold fewer colonies under anchorage independent conditions in three 
different invasive bladder cancer lines. Moreover, upon intravenous injection, 
the efficiency of Fra-1-depleted cells in forming colonies was significantly 
diminished.
 CRISPR was recently identified as a defense system against foreign 
DNA in prokaryotes [17]. Exploiting CRISPR/Cas systems for genome editing in 
eukaryotic cells is a new and efficient way of activating or repressing genes of 
interest [18,19]. We employed this system in order to avoid potential drawbacks 
of shRNAs such as remaining gene activity and negative selection against 
the construct. Bladder cancer cells lacking Fra-1 expression had reduced 
efficiency at invasion and anchorage-independent colony formation in vitro. 
Complete and permanent loss of Fra-1 massively reduced the metastatic 
spread of bladder cancer cells in vivo, sometimes to undetectable levels.
 MIBC is an aggressive and incurable disease. Radical cystectomy, 
radiotherapy and systemic therapy are the standard treatment options of 
MIBC [20]. Several lines of research aim to find biomarkers for diagnostic 
and therapeutic purposes [21-23]. Despite these efforts, none of the findings 
are effectively in use in the clinic due to reasons such as inefficiency or 
toxicity [24]. Our data suggest that Fra-1 is a potential prognostic biomarker in 
bladder cancer and that Fra-1 expression is a critical determinant of invasive 
phenotype in bladder cancer.
 Identification of Fra-1 as a predictive factor in bladder cancer has 
important implications for the future of bladder cancer treatment: not only 
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may we be able to stratify patients better, but we may also be able to develop 
targeted treatments for downstream effectors of Fra-1. Based on the Fra-1 
expression levels, or by generating a Fra-1 classifier similar to those in breast 
[13, 15] and colon [14, 25] cancers, we may explore distinguishing patients 
who are at risk of developing aggressive disease and adjust their course of 
treatment accordingly. Furthermore, because Fra-1 is a transcription factor 
regulating the expression of thousands of genes [15], drivers of the invasive 
phenotype can be identified and eventually targeted in the clinic. This strategy 
would provide a major advantage over existing regimens, since bladder cancer 
is very heterogeneous with regard to its mutational landscape [26], making 
it exceptionally difficult to develop genetic aberration-based treatment 
approaches. 
Materials and Methods
Cell Culture
HEK293T and bladder cancer cell lines (SD, T24, VmCub1) were cultured in 
DMEM supplemented with 2mM glutamine and 9% fetal bovine serum (Gibco). 
For lentivirus production, HEK293T cells were refreshed with complete 
medium containing 25 mM chloroquine, transfected with 8 μg of lentiviral 
construct and 4 μg of pMDLglpRRE, pHCMV-G, and pRSVrev and refreshed in 
complete medium after 6-8 hours. The lentivirus containing supernatant was 
used to transduce cell lines, followed by antibiotic selection when applicable. 
shRNA sequences targeting Fra-1 were custom designed and cloned into KH 
vector. The sequences were as follows: shFra-1(1): GTAGATCCTTAGAGGTCCT, 
shFra-1(2): GGCCTGTGCTTGAACCTGA. 
 A guide RNA for Fra-1 (CACCGGCCTTCGACGTACCCCTGG) was cloned 
into a lentiviral CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeats)/Cas9 vector.
 2D proliferation assays were carried out by seeding 3*104 cells/well 
in 6-well plates (Corning) and stained with crystal violet after 7 days. For 
3D proliferation assays, 2.4*104 cells were seeded in 0.4% low-melting-point 
agarose (Sigma) on 6-well plates (Corning) coated with a 1% agarose layer. 
The plates were scanned and colonies were counted by Image J software. For 
invasion experiments, matrigel-coated 6-well Boyden chambers were used (BD 
Biosciences). The wells were rehydrated for 2 hours with complete medium in 
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37°C. Cells were seeded in serum-free medium at 2.5x105 cells/chamber and 
the outer chamber was filled with complete medium to create a gradient. Inner 
chamber was refilled daily with serum-free medium to maintain the gradient. 
After 48-72 hours, non-invading cells in the inner chambers were scraped off 
by cotton swabs and the cells on the outer face of the membrane were stained 
with crystal violet.
Immunoblot analysis and antibodies
Cells were harvested by scraping in cold PBS and the pellets were lysed in 
RIPA buffer (50 mM TRIS pH 8.0, 150 mM NaCl, 1% Nonidet P40, 0.5% sodium 
deoxycholate, 0.1% SDS, complete protease inhibitor cocktail (Roche), and 
phosphatase inhibitors 10 mM NaF, 1 mM Na3VO4, 1 mM sodium pyrophosphate, 
10 mM beta-glycerophosphate). After centrifugation the protein concentrations 
were determined by Bio-Rad protein assay (Bio-Rad). Immunoblot analysis 
was performed by using 4-12% Bis-Tris polyacrylamide-SDS gels (NuPAGE) and 
transferring these on to nitrocellulose membranes (Amersham). Membranes 
were blocked in 4% skimmed milk powder dissolved in 0.2% Tween-containing 
PBS and incubated with primary antibodies followed by secondary antibodies 
(Invitrogen). Primary antibodies used were Fra-1 (sc-605, Santa Cruz 
Biotechnology) and Hsp90 (sc-7947, Santa Cruz Biotechnology). 
Tumor Xenografts and Bioluminescence Analysis
All animal work was done in accordance with a protocol approved by 
the Netherlands Cancer Institute Animal Experiment Ethics Committee. 
Female NOD/SCID/IL2gamma mice aged 5-8 weeks were used for all in vivo 
experiments. 0.2*106 or 0.5*106 cells were injected into the lateral tail vein 
in 150 ul PBS. For bioluminescence imaging, the mice were intraperitoneally 
injected with 15 mg/kg D-luciferin (Caliper Life Sciences) 15 minutes prior 
to imaging. The mice were anaesthetized and imaged with 60 seconds of 
exposure time (binning=8). The data was analyzed by Living Image software. 
Immunohistochemistry
Histological sections and hematoxylin-eosin staining were performed using 
standard procedures. Paraffin sections were deparaffinized, rehydrated, 
pretreated in 0.1 mM sodium citrate pH 6.0, washed and incubated with 
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peroxide. The tissue was incubated with primary antibodies for GFP (1:2000, 
Abcam). Secondary antibody was PowerVision (DPVB-999HRP, ImmunoLogic). 
Peroxidase activity was detected with Liquid DAB (K3468, DAKO).
Survival Analysis
Survival analysis was performed as described before  [13] by using a publicly 
available dataset (GSE13507).
Statistical analysis
Comparisons of two experimental groups were analyzed with two-tailed 
student’s t-test. One-Way ANOVA corrected for multiple comparisons (Holm-
Sidak) was used to compare more than two experimental groups (Prism; 
GraphPad Software). Error bars represent standard error of the mean (SEM).
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General Discussion
The two main mortality causes in cancer therapy are treatment resistance 
and metastasis. Unresponsiveness to available therapies renders the disease 
incurable. It therefore is important to have alternative treatment options. 
Metastasis is a more insidious aspect of cancer since metastatic growths 
are hard to detect when they are very small and they can occur in very high 
number. Moreover, metastasis can go hand in hand with acquisition of drug 
resistance, because metastases are often insensitive to therapy as well. In 
the work described in this thesis we explored novel targeted therapy options 
for TNBC and investigated the in vivo role of Fra-1 in metastasis of colon and 
bladder cancers.
The need for targeted therapies in TNBC
TNBC is an aggressive form of breast cancer with a worse prognosis compared 
with other subtypes of breast cancer. After surgical removal, 34% of the time 
tumors relapse [1] with the majority of them being chemoresistant [2]. Yet, the 
only treatment options are single-agent or combination chemotherapy, or 
radiotherapy. Due to its heterogeneity, there is no standard therapy regimen for 
TNBC; the choice of treatment course is dependent on individual factors such 
as tumor size, grade, and lymph node status [3]. Moreover, because there is no 
commonly mutated driver gene in TNBC, targeted therapy options are scarce. 
Despite the several ongoing clinical studies to assess the performance of 
alternative treatment methods alone or in combination with chemotherapeutic 
agents, the results are not sufficiently successful yet to be approved by the 
FDA for routine use in the clinic. Therefore, it is both crucial and urgent to 
develop effective new therapy options for TNBC. For these reasons, in chapters 
2 and 3 of this thesis we focused our research on TNBC.
Discovering new vulnerabilities in cancer
In the last few decades, targeted therapies arose as effective alternatives to 
chemo- and radiotherapy. By targeting tumor-specific dependencies, these 
therapies provide considerable benefit to patients. However, regardless of 
the treatment type, intrinsic and acquired drug resistances are challenges 
clinicians commonly encounter in anti-tumor therapy. For this reason, there 
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is constant effort to discover new drug targets as well as to develop new 
generation drugs that overcome therapy resistance.
 In chapter 2, we designed an in vivo loss-of-function genetic screen 
in TNBC cell lines in order to identify druggable molecules that can serve as 
potential targets in the clinic. Our screen and further validation experiments 
revealed that combined inhibition of EGFR and ROCK1 efficiently kills TNBC 
cells. Importantly, neither EGFR nor ROCK1 is mutated in any of the cell lines 
we used. With this approach we could induce cell death in multiple TNBC cell 
lines of different genetic backgrounds and demonstrate synthetic lethality 
between non-oncogenes, a recently described phenomenon.
 Although several TNBC cell lines responded to EGFRi-ROCKi 
combination treatment, there is also a group of cell lines whose fitness was 
not negatively influenced. For clinical purposes, it is important to understand 
the underlying cause of resistance and identify a marker to be able to predict 
response to this combination treatment.  In chapter 3, we therefore compared 
TNBC cell lines that are sensitive and insensitive to EGFRi-ROCKi combination 
treatment and found that Rab11 gene is differentially expressed between these 
two groups.
How to deal with metastasis in the clinic?
Metastatic recurrence is a major cause of cancer-related mortality. 
Because metastases start out as single or a small group of cells, 
detection of metastatic disease is often too late for intervention due to the 
size, number or location of the tumors(s). Lack of early detection methods 
and the fact that metastases are often resistant to previously used therapies 
in the same patient present a major challenge in the treatment of metastatic 
tumors. Therefore, there are methods in clinical use to predict aggressiveness 
of cancers and disease prognosis. Histological status, genetic markers, and 
gene expression classifiers are employed to stratify patients and design 
treatment regimens that are most likely to be beneficial. For instance, BRCA 
deficiency that is common in some cancers like breast and ovarian causes the 
cells to be sensitive to PARP inhibition [4]. Since this finding PARP inhibitors 
are being successfully used in the clinic to treat BRCA-mutant tumors [5]. Also, 
gene expression profiles can help predict disease prognosis and response to 
treatment. A 70-gene classifier in breast cancer is being used to help decide 
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whether or not early-stage breast cancer patients need adjuvant therapy [6, 7].
 In chapter 4, we have generated a Fra-1-based classifier in colon cancer 
where we demonstrate that the group of 197 genes that are regulated by Fra-1 is 
a powerful tool to predict colon cancer patient prognosis. Our RNA sequencing 
data show that the Wnt pathway is one of the major pathways regulated by 
Fra-1 and we propose that Wnt could be a potential therapeutic target in the 
treatment of invasive colon cancer.
Fra-1: a global regulator of metastasis in all cancers
Fra-1 is a member of the AP-1 family of transcription factors and is mainly 
involved in migration, invasion and metastasis. Our group previously showed 
that Fra-1 is a downstream effector of TrkB [8], an oncogene that mediates 
anoikis resistance, tumorigenesis, and metastasis [9, 10]. The in vitro role of 
Fra-1 in cell motility is demonstrated in numerous studies [11-13]. Also in vivo, 
we and others have shown that Fra-1 is a major determinant of the metastatic 
potential of breast cancer cells [8, 14] while other studies highlighted the in 
vivo importance of Fra-1 also in pancreatic cancer [15] and squamous cell 
carcinoma [16]. Most recently, our group has identified a genetic and prognostic 
Fra-1-dependent network driving human breast cancer, comprising several 
potentially druggable targets [17].
 In chapters 4 and 5, we show that Fra-1 is essential for the in vivo 
spread of colon and bladder cancer cell lines. Our data, combined with the 
previous reports on the Fra-1-mediated regulation of cell motility and tumor 
metastasis, indicate that the role of Fra-1 is not restricted to a particular cancer 
type and suggest that Fra-1 is a master regulator of metastasis in cancer. 
Interestingly, our datasets on genes regulated by Fra-1 in breast [8], colon [18] 
and bladder(unpublished data) cancers did not reveal any common molecules. 
Fra-1 is an immediate early gene that regulates over a thousand genes at 
different times. It therefore is conceivable that, based on the tissue type the 
route Fra-1 takes to modulate a certain function varies.
Concluding remarks
Despite extensive research and resulting advancements in the clinical care of 
cancer patients, there are still a lot of people that cannot be helped by modern 
medicine. Discovering novel approaches for cancers that cannot be efficiently 
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treated with conventional therapies is a constant focus of cancer research. 
The main reasons of cancer being a life-threatening disease are therapy 
resistance and metastasis. In this thesis, we addressed both of these issues 
by uncovering a novel combination treatment for TNBC, and by showing the 
essential role of Fra-1 in metastasis in vivo and its prognostic significance for 
colon and bladder cancer patients.  
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Summary 
Cancer is an abnormal growth in a part of the body, caused by uncontrolled 
division of cells forming a tumor. In principle, tumors can be surgically removed 
so that they would not pose a health risk to the patients anymore. However, there 
are cases where the tumors are inoperable due to their location or the fitness 
of the patient. Such tumors, and non-solid tumors of the blood and lymphatic 
system, have to be fought against by drugs. Moreover, surgical operations still 
have the risk of having reminiscent cancer cells that can regrow as tumors. 
Therefore, even when surgery is possible, patients still receive therapy as an 
extra measure. Most cancer patients undergo systemic chemotherapy, which 
causes several side effects. As an alternative, several less invasive targeted 
therapies have been developed where a specific molecule or pathway is 
targeted via inhibitors or antibodies. Unfortunately, such drug treatments also 
do not ensure a definitive cure owing to therapy resistance caused by factors 
like tumor heterogeneity, secondary mutations, parallel pathway activation, 
and feedback mechanisms. In fact, drug resistance is a major factor in relapse 
of many malignancies. A minority of cells that are unresponsive to the 
treatment(s) due to either intrinsic or acquired resistance eventually grow out. 
Nowadays, this phenomenon is so common that most therapies are designed 
as combinatorial treatments with two or more drugs. Although important, drug 
resistance is not the sole reason of recurrence. Metastasis is another major 
cause of relapse and one of the hallmarks of cancer. Many tumors resurface 
at a distant site, formed by the cells that escaped from the primary location 
and any localized treatment such as surgery or radiation therapy. Metastasis 
is a very complex process and is still poorly understood despite extensive 
research. In this thesis, we focused on these two distinct aspects that lead to 
fatal cancer progression. 
 In Chapter 1 we give a brief introduction to targeted therapies and 
approaches to circumvent the obstacle of drug resistance. We also describe 
the dynamic process of metastasis and why it is important to understand 
metastatic capability of cancer in more detail. 
 Chapter 2 of this thesis focuses on finding an effective targeted 
combination treatment for triple-negative breast cancer (TNBC), a breast 
cancer subtype that is currently being treated only with surgery, chemotherapy, 
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radiotherapy or combinations of these. We aimed to discover novel targeted 
therapies for TNBC and found that combination of EGFR and ROCK inhibitors 
leads to cell cycle arrest and the eventual death of TNBC cells. 
 Understanding the underlying mechanism of drug response is crucial 
to develop more effective approaches. Therefore, in Chapter 3 we tried to shed 
light on why combined inhibition of EGFR and ROCK leads to cell death in 
TNBC cells. We found that, this combination of inhibitors simultaneously leads 
to induction of autophagy and inhibition of rpS6, a molecule crucial for various 
cellular processes.
 Chapter 4 and Chapter 5 focus on the role of the transcription factor 
Fra-1 in metastasis. We established the in vivo significance of Fra-1 in colon 
and bladder cancer cell lines by experimental metastasis models. Moreover, 
our analyses show that Fra-1 on its own is a predictive marker in bladder 
cancer while in colon cancer the group Fra-1-regulated genes have prognostic 
power to stratify patients based on their gene expression profiles.
 In conclusion, this thesis proposes a novel targeted therapy approach 
for TNBC and signifies the essential role of Fra-1 in the regulation of metastasis 
as well as in disease prognosis.
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Samenvatting
Kanker is een abnormale groei in een deel van het lichaam die wordt 
veroorzaakt door ongecontroleerde deling van cellen. In principe kunnen 
tumoren operatief worden verwijderd, zodat ze geen gezondheidsrisico meer 
vormen voor de patiënten. Er zijn echter veel gevallen waarin tumoren vanwege 
hun locatie of vanwege de lichamelijke conditie van de patiënt niet-operabel 
zijn. Dergelijke tumoren, en niet-solide tumoren van bloed en het lymfatische 
systeem, moeten met medicijnen bestreden worden. Bovendien bestaat er nog 
steeds een kans dat tijdens een chirurgische ingreep niet alle kankercellen 
verwijderd worden met de mogelijkheid dat deze cellen zich later opnieuw tot 
tumoren kunnen ontwikkelen. Daarom - zelfs wanneer een operatie mogelijk 
is - ontvangen patiënten vaak aanvullende therapie om de achterblijvenden 
tumorcellen te bestrijden. De meeste kankerpatiënten ondergaan systemische 
chemotherapie, die verschillende ernstige bijwerkingen heeft. Als een 
alternatief voor chemotherapie zijn er verschillende, minder invasieve, 
gerichte therapieën ontwikkeld. Het remmen van een specifiek molecuul of 
een specifieke signalerende cascade is het werkingsmechanisme van deze 
therapie. Helaas garanderen dergelijke medicamenteuze behandelingen 
geen definitieve genezing vanwege geneesmiddelenresistentie. Deze 
resistentie wordt veroorzaakt door tumorheterogeniteit, secundaire mutaties, 
parallelle route-activering of verschillende feedbackmechanismen en is 
deze resistentie feitelijk een belangrijke factor bij terugkomst van vele 
maligniteiten. Een deel van een tumor die als gevolg van intrinsieke of 
verworven resistentie op de behandeling(en) niet reageert, blijft groeien 
en kan uiteindelijk een secundaire tumor vormen. Tegenwoordig komt 
dit fenomeen zo vaak voor dat de meeste therapieën zijn ontworpen 
als gecombineerde behandelingen met twee of meer geneesmiddelen. 
Geneesmiddelenresistentie is een belangrijke, maar niet de enige reden 
voor de terugkomst van een tumor. Metastasering is een andere belangrijke 
oorzaak en ook een van de belangrijke kenmerken van kanker. Terugkerende 
tumoren verschijnen vaak op een andere plaats in het lichaam dan de initiële 
tumor. Ze worden gevormd door cellen die aan gelokaliseerde behandelingen 
zoals een operatie of bestralingstherapie zijn ontsnapt. Metastasering 
is een zeer complex proces en wordt ondanks uitgebreid onderzoek nog 
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steeds slecht begrepen. In dit proefschrift hebben we ons gericht op deze 
twee verschillende aspecten die leiden tot fatale progressie van kanker.
 In Hoofdstuk 1 geven we een korte introductie in gerichte therapieën 
en benaderingen die resistentie tegen geneesmiddelen proberen te omzeilen. 
Daarnaast beschrijven we het dynamische proces van metastasering en 
de rol van onderzoek naar metastasering om kanker beter te begrijpen.
 Hoofdstuk 2 van dit proefschrift richt zich op het vinden van een 
effectieve gerichte combinatietherapie voor triple-negatieve borstkanker 
(TNBC). TNBC is een subtype van borstkanker die momenteel alleen met chirurgie, 
chemotherapie, radiotherapie of combinaties hiervan wordt behandeld. We 
hebben getest wat het effect is van nieuwe doelgerichte therapieën op TNBC en 
we vinden dat de combinatie van EGFR- en ROCK-remmers de ongecontroleerde 
groei van TNBC-cellen remt en uiteindelijk tot de dood van TNBC-cellen leidt.
 Het is van cruciaal belang om het onderliggende mechanisme 
van de reactie op geneesmiddelen te begrijpen om effectievere 
benaderingen te ontwikkelen. Daarom probeerden we in Hoofdstuk 3 
te verklaren waarom de gecombineerde remming van EGFR en ROCK 
tot de dood van TNBC-cellen leidt. We vinden dat deze combinatie van 
remmers gelijktijdig leidt tot de inductie van autofagie en de remming 
van rpS6, een molecuul cruciaal voor verschillende cellulaire processen.
 In Hoofdstuk 4 en Hoofdstuk 5 bestuderen we de rol van de 
transcriptiefactor Fra-1 in het proces van metastasering. Aan de hand van 
experimentele metastase modellen stellen we de belangrijke rol van Fra-1 in 
in vivo groei van colon- en blaaskankercellijnen vast. Bovendien laten we zien 
dat Fra-1 op zichzelf een voorspellende waarde heeft bij blaaskanker, terwijl 
bij dikke darmkanker de Fra-1-gereguleerde genen prognostische waarde 
hebben om patiënten op basis van hun genexpressieprofielen te stratificeren.
 Concluderend, in dit proefschrift beschrijven we een nieuwe effectieve 
gerichte therapie voor TNBC en laten we zien dat Fra-1 een essentiële rol heeft 
zowel in de regulatie van metastasering als in de prognose van de ziekte.
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